The reversed intra- and extracellular pH in tumors as a unified strategy to chemotherapeutic delivery using targeted nanocarriers

Edgar Pérez-Herrero, Alberto Fernández-Medarde

Solid tumors are complex entities, comprising a wide variety of malignancies with very different molecular alterations. Despite this, they share a set of characteristics known as “hallmarks of cancer” that can be used as common therapeutic targets. Thus, every tumor needs to change its metabolism in order to obtain the energy levels required for its high proliferative rates, and these adaptations lead to alterations in extracellular and intracellular pH. These changes in pH are common to all solid tumors, and can be used either as therapeutic targets, blocking the cell proton transporters and reversing the pH changes, or as means to specifically deliver anticancer drugs. In this review we will describe how proton transport inhibitors in association with nanocarriers have been designed to block the pH changes that are needed for cancer cells to survive after their metabolic adaptations. We will also describe studies aiming to decrease intracellular pH in cancer using nanoparticles as molecular cages for protons which will be released upon UV or IR light exposure. Finally, we will comment on several studies that have used the extracellular pH in cancer for an enhanced cell internalization and tumor penetration of nanocarriers.

KEY WORDS
pH-Gradient inversion; Metabolism of glucose; Proton transport inhibitors; Proton-caged carriers; Chemotherapy; Targeted drug delivery; pH-Sensitive nanocarriers; Warburg effect; Cancer
and a controlled drug delivery, describing how nanocarriers are being used to increase drug stability and specificity.

© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

From old, humanity has search for a miracle cure for all diseases, a pill that cures it all. This has also been true in the search for a general treatment for cancer. Unfortunately, the term “cancer” comprises a vast amount of diseases, developed through the accumulation of a varied set of genetic alterations, making every patient unique1-2. This has forced healthcare professionals to use a battery of individual therapeutic strategies for each type of cancer, but in spite of this individualized approach, and because of their genetic heterogeneity, every patient will have a different response to the treatment, and many will die due to the illness. Notwithstanding their genetic heterogeneity, all liquid and solid tumors have many features in common, which are related to the physiological, biochemical and molecular mechanisms that lead to the initiation of the tumor, its progression and metastasis3. These shared characteristics are known as the hallmarks of cancer, and include: deregulated proliferation, apoptosis avoidance, escape from the immune system, the acquisition of an invasive phenotype, induction of angiogenesis, obtaining replicative immortality, genetic instability and altered cell energetics4. These common features may allow us to search for a unified strategy that could allow to fight against cancer as a whole. Indeed, several therapeutic strategies have already been used to target some of those hallmarks: drugs that block proliferation or inhibit angiogenesis have been used in the clinic for years5, and the approach to enact an immune response against tumors has seen a revolution in the last ten years6. In spite of these advances, many cancers are still incurable, and for those, the cure might be found among the other hallmarks.

In this regard, Otto Warburg discovered almost 100 years ago a common and unique characteristic of solid tumors that differentiate them from the normal tissue. Cancer cells show an abnormal metabolic behavior in which the metabolism of glucose through the glycolytic pathway to lactate has a predominance over the degradation through the tricarboxylic acid (TCA) cycle and oxidative phosphorylation. These metabolic changes are now considered a hallmark of cancer, an adaptation necessary for tumor development7. In healthy cells, in the presence of physiological levels of oxygen, TCA cycle and oxidative phosphorylation are the main pathways used to degrade the pyruvate generated through glycolysis, because they are the most efficient metabolic pathways to obtain adenosine triphosphate (ATP) from glucose (36/38 ATPs per glucose). Cellular metabolism in cancer shift glycolysis to generate lactate from pyruvate (which is known as “aerobic glycolysis”), in order to adapt to the hypoxic conditions found in many tumor areas (Pasteur effect), because this metabolic pathway is able to produce energy in the absence of normal levels of oxygen. Recently, this notion has been proved to be partially wrong, since aerobic glycolysis is also observed in the presence of oxygen in tumor cells. This raises an obvious question: why is this aerobic glycolysis chosen by the tumor cells despite being so inefficient (only 1 ATP per glucose)? The answer is speed: aerobic glycolysis is almost 100 times faster than complete degradation of glucose by TCA cycle and oxidative phosphorylation. In addition, aerobic glycolysis is thought to be necessary to complement the oxidative phosphorylation in order to fulfill the increased energetic demands of highly proliferative cancer cells8. This metabolic shift must be necessary for tumor initiation because the appearance of the aerobic glycolysis is an early event in the oncogenic transformation9. In these initial stages of tumor development, the change to this metabolic route might be facilitated by the role of several oncogenes that are increasing glucose metabolism10. This is the case for the RAS GTPases, oncogenes mutated in a 30% of human malignancies, which activate PI3K signaling, a key regulator of glycogen degradation, glucose uptake and expression of glycolytic enzymes such as hexokinase 2 and phosphofructokinase 1 (Fig. 1). In addition, activating mutations in PI3K or deleterious mutations in the tumor suppressor PTEN (a negative regulator of this pathway) are frequent events in cancer. Another oncogene that is implicated in the control of glycolysis is MYC. This transcription factor, overexpressed in many cancers, is known to induce the expression of pyruvate kinase or lactate dehydrogenase (LDHA), thus activating the aerobic glycolysis (Fig. 1). As already mentioned, aerobic glycolysis might be an additional mechanism to obtain energy for tumor cells when normal oxygen levels are present but is a necessity in tumor areas where the access to oxygen is scarce. In hypoxic conditions, cancer cells adapt their metabolism through the expression of hypoxia inducible factor (HIF1). This protein induces the expression of most enzymes regulating the normal glycolytic pathway, as well as LDHA in the aerobic glycolysis. In addition, it inhibits pyruvate dehydrogenase avoiding pyruvate degradation via TCA cycle and oxidative phosphorylation and, thus increasing its transformation to lactate11.

As a consequence of the metabolic shift in cancer, the degradation of glucose in malignant cells by aerobic glycolysis will lead to the production of large amounts of lactic acid and a concomitant increase in proton (H+) concentration inside the cancer cells. For this reason, in order to avoid the apoptotic response that would induce this acid stress, malignant cells use several mechanisms to extrude this excess of H+ from the cytoplasm by plasma membrane-bound proton transporters and proton pumps that are upregulated in tumors, provoking a decrease of the tumor extracellular pH (pHe) and a concomitant increase of the intracellular pH (pHi)11 (Fig. 1). The increase in pHe observed inside the cancer cells is not only produced by the overexpression of H+ extrusion systems, but also because of the decrease in the CO2 production consequence of the reduction of the TCA cycle and oxidative phosphorylation12. Intracellular alkalinity helps avoid apoptosis, induces an increase in the proliferation of malignant cells through induction of G2/M transition and is directly related to the development of multiple drug resistance (MDR). Moreover, acidic pHe promotes invasion and metastasis, and increases MDR, angiogenesis and tumor immune escape12-14.
As already mentioned, the altered pH of the cancer cells has a positive impact on the development of many cancer hallmarks. Thus, the inversion of this reverse pH gradient (pH$_{\text{tumor}}$ > pH$_{\text{c}}$) in tumors is being used to design promising new treatments in cancer. Some of the approaches used to date tried to induce acid stress inside the cancerous cells in order to force apoptosis either by a) inhibition of the proton extruder systems, b) increasing lactic acid production with molecules that diminish the mitochondrial activity, c) inducing lysosomal membrane permeabilization or d) generating intracellular acidification with non-proton acidifiers or light-activated proton carriers$^{8,11,15}$. Other interesting approaches take advantage of the slightly acidic extracellular microenvironment of tumors for drug delivery, using cytotoxic substances and/or carriers that are more active and/or change its physical–chemical properties at the pH$_{\text{c}}$.$^{16}$ As mentioned above, extracellular acidification favors tumor dissemination and other laboratories have aimed to revert this abnormal pH$_{\text{c}}$ as a therapeutic approach$^{17}$. Finally, the overexpressed proton pumps in tumors can be the basis for targeted therapies in cancer, either by their direct inhibition or as molecular identifiers of the tumoral cells that could be used for recognition in the delivery of cytotoxic drugs$^{18}$.

Nanocarriers have been commonly used as vehicles of anticancer agents in indirect targeted therapies. Their custom design allows their specific accumulation and/or release in tumors, bypassing normal tissues, which highly reduces drug toxicity and provides protection from degradation. It also increases several-fold drug accumulation in the tumors, allowing the use of lower drug concentrations. In addition, nanocarriers reduce the mononuclear phagocyte system (MPS) clearance and improves the control over the release kinetics$^{19}$. Moreover, nanocarriers can be designed to take advantage of the pH-centric paradigm and use this as a unified strategy to fight against cancer, regardless of the pool of genetic alterations in the tumor. In this review, we will analyze in detail some of the late developments in nano-scale carriers that aim to take advantage of the abnormal intra- and extracellular pH in tumors for targeted therapies.

2. Proton transport inhibitors and nanocarriers

Proton transport in the cells is the key in the regulation of numerous physiological functions. In addition to maintaining the intracellular pH in the physiological values (≈7.2), they are also used to generate electrical and chemical gradients needed for the transport of metabolites, and the proton accumulation, generated by the electron transport chain in the inner membrane of the mitochondria, is used to generate ATP by the ATP synthase$^{20,21}$. Malignant cells overexpress different plasma membrane-bound proton transporters (PTs) and proton pumps (PPs, Tables 1–4), such as Na$^+$/H$^+$ exchange-1 (NHE1), monocarboxylate-H$^+$ co-transporters or MCTs (mainly MCT1 and 4 isoforms), carbonic anhydrases or CAs (mainly CA9 and CA12 isoforms), bicarbonate transporters (mainly Na$^+$/HCO$_3^-$ co-transporters or NBCs) and vacuolar ATPase proton pumps (V-ATPases)$^{22,23}$. These upregulated proton extruder systems avoid intracellular acidification and therefore apoptosis in cancer cells, inducing alkalization of the cytoplasm (to ≈ pH 7.4) and extruding the excess of protons to the extracellular environment that changes from pH 7.4 in normal tissues to pH 6.5–7.0 in tumors. Although these
Table 1  Vacuolar ATPases in cancer.

| Cancer          | ATP6V0A1 | ATP6V0A2 | ATP6V0A3 | TCIRG1 | ATP6V0A4 | ATP6V0B | ATP6V0C | ATP6V0D1 | ATP6V0D2 | ATP6V0E1 | ATP6V0E2 | ATP6V1A | ATP6V1B1 | ATP6V1B2 |
|-----------------|----------|----------|----------|--------|----------|--------|--------|----------|----------|----------|----------|--------|----------|----------|
| Adrenal gland   | 16.46    | 20.25    | n/a      | 11.39  | n/a      | 10.13  | 75.95  | 11.39    | 32.91    | 11.39    | 7.59     | 13.92  | 20.85    | 6.19     |
| Breast          | 5.53     | 6.61     | 4.44     | 3.89   | 4.89     | 3.89   | 3.53   | 3.53     | 3.53     | 3.53     | 3.53     | 3.53   | 3.53     | 3.53     |
| CNS             | 3.73     | 4.73     | 5.6      | 3.87   | 3.87     | 3.87   | 4.02   | 4.02     | 4.02     | 4.02     | 4.02     | 4.02   | 4.02     | 4.02     |
| Cervix          | 2.93     | 0.33     | 4.89     | 2.28   | 4.23     | 4.23   | 4.23   | 4.23     | 4.23     | 4.23     | 4.23     | 4.23   | 4.23     | 4.23     |
| Endometrium     | 5.15     | 6.98     | 4.65     | 2.82   | 4.65     | 4.65   | 4.65   | 4.65     | 4.65     | 4.65     | 4.65     | 4.65   | 4.65     | 4.65     |
| Hematop. & Lymph. | 2.71   | 5.88     | 5.88     | 5.43   | 5.43     | 5.43   | 5.43   | 5.43     | 5.43     | 5.43     | 5.43     | 5.43   | 5.43     | 5.43     |
| Kidney          | 5.83     | 5.17     | 8        | 3.5    | 2.67     | 2.67   | 2.67   | 2.67     | 2.67     | 2.67     | 2.67     | 2.67   | 2.67     | 2.67     |
| Large intestine | 7.38     | 6.23     | 3.28     | 4.26   | 6.39     | 6.39   | 6.39   | 6.39     | 6.39     | 6.39     | 6.39     | 6.39   | 6.39     | 6.39     |
| Liver           | 8.04     | 7.77     | 9.12     | 6.7    | 5.36     | 5.36   | 5.36   | 5.36     | 5.36     | 5.36     | 5.36     | 5.36   | 5.36     | 5.36     |
| Lung            | 2.45     | 4.32     | 2.45     | 6.48   | 6.28     | 6.28   | 6.28   | 6.28     | 6.28     | 6.28     | 6.28     | 6.28   | 6.28     | 6.28     |
| Oesophagus      | 4        | 11.2     | 1.6      | 4.8    | 2.4      | 3.2    | 0.8    | 8*       | 6.4      | 10.4     | 2.4     | 4      | 10.4     | 2.4      |
| Ovary           | 1.5      | 6.02     | 3.76     | 3.76   | 10.15    | 1.5    | 2.26*  | 1.88     | 5.64     | 6.02     | 10.9    | 7.89   | 2.63*    | 7.29     |
| Pancreas        | 7.82     | 3.91     | 1.68     | 2.23   | 3.35     | 3.91   | 8.94   | 3.55     | 4.47     | 4.47     | 3.55    | 4.47   | 3.55     | 4.47     |
| Prostate        | 3.01     | 4.82     | 4.82     | 2.81   | 6.28     | 5.02   | 4.82   | 4.82     | 4.82     | 4.82     | 4.82     | 4.82   | 4.82     | 4.82     |
| Skin            | 4.44     | 5.07     | 3.17     | 0.63   | 6.55     | 5.29   | 1.69   | 4.02     | 9.09     | 4.23     | 1.06    | 2.75   | 4.23     | 1.06     |
| Soft tissue     | 6.08     | 4.56     | 1.14     | 1.52   | 7.22     | 9.51   | 2.66   | 3.42     | 4.94     | 3.04     | 3.04    | 1.52   | 3.04     | 1.52     |
| Stomach         | 8.42     | 6.67     | 5.26     | 3.51   | 7.02     | 6.67   | 8.77   | 5.96     | 5.26     | 3.86     | 5.26    | 3.86   | 5.26     | 3.86     |
| Thyroid         | 3.51     | 3.7      | 3.24     | 0.58   | 3.9      | 7.8    | 8.77   | 1.95     | 5.46     | 2.92     | 3.9     | 3.12   | 3.9     | 3.12     |
| Upper aerodig. tract | 3.07   | 7.09     | 6.13     | 2.11   | 5.94     | 5.75   | 5.75   | 3.26     | 4.6      | 3.07     | 12.64   | 1.15   | 2.87     | 1.15     |
| Urinary tract   | 2.94     | 5.39     | 1.72     | 3.19   | 5.39     | 2.94   | 5.15   | 3.92     | 3.19     | 9.31     | 8.09    | 0.98   | 1.72     | 0.98     |

Overexpression levels of the vacuolar ATPase family members in cancer affecting several tissues. 
Overexpression >20% in bold letters. 
n/a, not available. 
Asterisks: also downregulated in some patients.
*5%–10%.
†10%–15%. 
changes of pH look small, they have a huge impact in the cells and their environment and blocking these PTs and PPs is a promising therapeutic approach that is currently being exploited as an anti-cancer strategy. Moreover, since an acidic pH increases MDR reducing the therapeutic efficacy of antineoplastic drugs, the use of proton transport inhibitors (PTIs) and proton pump inhibitors (PPIs) might be a good option as an adjuvant strategy to improve the effects of chemotherapy.

2.1. Vacuolar ATPases (V-ATPases) inhibition

V-ATPases are proton pumps that use ATP hydrolysis to provide energy for $H^+$ transport from the cytoplasm to the lumen of internal compartments or the extracellular media. They are used in normal cells for acidification of lysosomal lumen, transport of metabolites, etc. In cancer, V-ATPases have been described to play a role in tumor microenvironment acidification, and an elevation of V-ATPase levels has been associated with increased invasion and metastasis. V-ATPases are overexpressed in many types of cancer and the $ATP6V1C1$ gene is highly expressed in many human cancers, especially liver, ovary, and colorectal. Increased expression levels from the genes $ATP6V1H$, $ATP6AP1$, $ATP6AP2$, and $VMA21$ have also been found in several tumors. In addition, V-ATPases are commonly targeted to the plasma membrane in tumors and these transporters are needed for signaling through several important pathways in tumor progression, such as WNT, NOTCH and MTOR.

Some drugs, like lansoprazole, pantoprazole, esomeprazole, omeprazole, and rabeprazole are PPIs that block the gastric $H^+\text{-}K^+$ ATPases and are currently being used in the treatment of acid-related disorders. In fact, Alai et al. developed different nanoparticulate oral delivery systems for the sustained release of lansoprazole (LPZ) all day long in the treatment of gastric ulcers and to avoid nocturnal acid secretions. These authors prepared positively charged LPZ-loaded nanoparticles (NPs) based on the non-biodegradable and bio-adhesive Eudragit RS100 and the oil-in-water (o/w) emulsion solvent evaporation method. They also formulated negatively charged LPZ-NPs using poly (lactic-co-glycolic acid) (PLGA) and the double emulsion (w/o/w) solvent evaporation method. Both formulations showed in vitro and in vivo sustained release profiles for up to 24 h and healing values higher that 90% in gastric ulcers in rats after 7 days of daily oral administration.

Figure 2  Mechanism of action of lansoprazole. In acidic environments the sulfoxide residue in lansoprazole is transformed into a sulfenic acid, which can bind to cysteine 813 in the ATPase and inhibit proton transport to the stomach lumen. These inhibitors can be used in cancer to block acidification of the tumor microenvironment, but also to induce a reduction in intracellular pH that would lead to cell death.

![Figure 2](image-url)
values for both drugs higher than 80% and 40%, respectively, and a controlled release of PTX and LPZ over 384 h, following a Fickian diffusion. The PTX-LPZ-loaded PLGA NPs produced a higher decrease in the cell viability of MCF7 breast cancer cells when compared with the combined free drugs after 48 and 72 h. The authors justified the enhanced cytotoxicity of the encapsulated PTX and LPZ because of high concentrations of both drugs inside the cells, due to the rapid uptake of NPs, and controlled release profiles produced by the diffusion of the drugs across the polymer matrix.

Despite the advantages of using targeted nanocarriers in combination with V-ATPase inhibitors to enhance the delivery of weakly basic chemotherapeutic agents, to the best of our knowledge, apart from the reports by Paskevičiūtė et al. and Bhattacharya et al. (Table S1), no other papers have been published in this regard.

2.2. Na⁺/H⁺ exchangers (NHE) inhibition

The SLC9A solute carriers is a family of Na⁺/H⁺ exchangers (NHE) implicated in the control of intracellular pH and cell proliferation. It is comprised of nine members, but only NHE1 is ubiquitous and is thought to have a central role in the movement of protons through the plasma membrane in most tissues and cell

| Cancer            | NHE1 | NHE2 | NHE3 | NHE3R1 | NHE3R2 | NHE4 | NHE5 | NHE6 | NHE7 | NHE8 | NHE9 |
|-------------------|------|------|------|--------|--------|------|------|------|------|------|------|
| Adrenal gland     | n/a  |      | 22.78| 1.27   | 2.53   | 8.86 | 15.19| 5.06 | 35.44| 11.39| 32.91|
| Liver             | 2.54 | 5.62 | 5.89 | 15.49  | 7.88   | 1.9  | 3.8  | 10.14| 5.89 | 15.49| 3.35 |
| Lung              | 4.59 | 4.59 | 4.45 | 4.73   | 3.59   | 6.31 | 3.73 | 6.31 | 2.58 | 7.03 | 4.3  |
| Endometrium       | 3.58 | 3.58 | 4.56 | 7.17   | 2.93   | 1.63 | 9.45 | 22.8 | 6.31 | 8.79 | 11.07|
| Hematop. & Lymph. | 3.16 | 3.16 | 4.32 | 3.82   | 5.48   | 3.65 | 9.3  | 5.81 | 8.47 | 8.31 | 3.65 |
| Kidney            | 4.07 | 1.36 | 3.62 | 4.07   | 4.07   | 5.43 | 6.33 | 4.07 | 4.52 | 4.07 | 2.71 |
| Large intestine   | 4.33 | 3.33 | 5.67 | 4     | 6.33   | 0.83 | 7    | 7.33 | 8    | 4.17 | 5    |
| Liver             | 2.46 | 4.92 | 5.57 | 4.26   | 7.05   | 3.28 | 7.05 | 12.46| 9.84 | 24.92| 4.1  |
| Lung              | 3.22 | 2.95 | 3.22 | 16.89  | 2.95   | 3.49 | 5.36 | 15.28| 8.58 | 5.36 | 3.75 |
| Pancreas          | 2.36 | 7.16 | 4.32 | 4.91   | 3.53   | 5.4  | 6.38 | 9.62 | 8.73 | 5.4  | 10.11|
| Oesophagus        | 7.2  | 4    | 4    | 10.4   | 2.4    | 3.2  | 25.6 | 6.4  | 1.6  | 44.01| 10.4 |
| Ovary             | 1.5  | 3.38 | 13.53| 7.52   | 2.26   | 7.52 | 0.38 | 8.65 | 3.38 | 5.64 | 1.13 |
| Pancreas          | 3.35 | 9.5  | 5.59 | 6.15   | 6.15   | 6.7  | 4.47 | 12.29| 11.2 | 6.15 | 4.47 |
| Prostate          | 3.82 | 4.82 | 2.21 | 5.22   | 5.62   | 4.62 | 3.01 | n/a  | n/a  | 3.41 | 6.22 |
| Skin              | 4.44 | 0.85 | 7.61 | 2.75   | 2.96   | 2.96 | 9.73 | 7.4  | 16.28| 14.8 | 2.54 |
| Soft tissue       | 6.84 | 6.08 | 1.52 | 3.04   | 2.28   | 3.8  | 4.56 | 0.76 | 18.25| 12.93| 6.46 |
| Stomach           | 4.56 | 11.93| 11.23| 7.37   | 5.26   | 7.72 | 5.96 | 6.32 | 11.93| 16.84| 2.46 |
| Thyroid           | 3.51 | 3.12 | 0.19 | 3.9    | 5.46   | 0.58 | 1.95 | 4.87 | 3.31 | 2.53 | 3.51 |
| Upper aerodig. tract | 5.56 | 3.07 | 4.98 | 6.13   | 5.75   | 2.87 | 5.56 | 7.85 | 4.6  | 5.75 | 10.92|
| Urinary tract     | 4.17 | 8.82 | 3.92 | 5.39   | 4.17   | 9.8  | 7.84 | 3.92 | 6.13 | 11.76| 2.7  |

Overexpression levels of the Na⁺/H⁺ exchanger (NHE) family members in cancer affecting several tissues. Asterisks: also downregulated in some patients.
Overexpression >20% in bold letters.

n/a, not available.

a(5%–10%).
b(10%–15%).
types. NHE2-5 are also plasma membrane transporters, but their role is limited to specific tissues, meanwhile NHE6-9 are located in intracellular organelles. The importance of NHE1 in overall pH regulation is emphasized by its role in cancer. In fact, to date, among this family only NHE1 has been clearly implicated in tumor formation and dissemination, and its elimination blocks tumor growth in nude mice, marking it as a possible therapeutic option in cancer.

Despite the absence of published work regarding the implication of other members of this family in cancer, a search on the COSMIC database for alterations in NHE expression in cancer showed that NHE8 gene is overexpressed in many esophagus tumors, where 44% of the samples tested showed NHE-8 overexpression (Table 2). Note that, although the implication of NHE1 is well established in literature, low rates of overexpression are shown in Table 2, which can be explained because of the low amount of data compiled for this gene in COSMIC. Unfortunately, the only NHE1 inhibitor to reach clinical trials, cariporide, had to be removed due to its cardiotoxicity.

2.3. Monocarboxylate–H\(^+\) co-transporters (MCTs) inhibition

Monocarboxylate–H\(^+\) co-transporters (MCTs) link the transport of protons and several metabolites through the plasma membrane. Each transporter is specific for one or several metabolites and has an important role in the regulation of cellular processes and metabolic pathways such as gluconeogenesis, thyroid hormone metabolism, T-cell activation, etc. Among these transporters, MCT1 and MCT4 have shown a clear pattern of overexpression in many types of cancer, where they function as regulators of the lactate metabolism promoting the metabolic changes observed in cancer as well as inducing angiogenesis and cell migration.

Table 3 shows the overexpression rates for the members of the MCT family in several types of cancer. Despite the apparently low overexpression rates shown in the COSMIC database for the individual MCTs in individual types of cancer, the added overexpression of the members of this family in cancer is very high, stressing their importance in pH regulation in tumors.

The overexpression of these transporters can be used as a therapeutic target to specifically deliver chemotherapeutic agents inside nanocarriers towards the cancer cells (Table S1). In fact, Calori et al. prepared 100 nm alpha-cyano-4-hydroxycinnamic acid (CHCA)-coated liposomes by the ethanol injection method, where CHCA acts as ligand to target MCT1 in MCF-7 and U-87 MG cancer cells and reduces oxidative stress because of their antioxidant properties. The authors reported an enhanced uptake of the carriers over the control in MCF-7 (26%) and U-87 MG (63%) cell lines using a concentration of CHCA of 50 \(\mu\)mol/L. Moreover, they demonstrated the antioxidant properties of CHCA, including aluminum chloride phthalocyanine in the liposomes as photosensitizer. In this way, they produced in situ oxidative stress in the cells by laser irradiation at 670 nm and they measured the decrease in cell death in the presence of CHCA.

Moreover, several pharmaceutical companies have developed inhibitors for MCTs, although only AZD3965, a MCT1 inhibitor, is now in clinical trials. Huang et al. prepared 33 nm
AZD3965-loaded PEG-b-(poly (dipropylaminoethyl) methacrylate) (PDPA) micelle nanoparticles (AZD-PDPA NPs) generated by nanoprecipitation method with microfluidics to inhibit MCT1 in cancer cells and reduce tumor immune evasion. The pH-sensitive characteristics of the system permitted the targeted delivery of all the MCT1 inhibitor contained in the carrier, which remained intact in blood circulation at physiological pH, until it reached the tumor, where the extracellular acidic pH (pHe) generated their immediate release because of the disassembly of the carriers. The authors demonstrated the protection of the drug within the AZD-PDPA NPs at physiological pH and the similar activity of free AZD3965 and AZD-PDPA NPs (with acidic pretreatment) in TC-1 cancer cells by measuring the presence of lactate and the variation of pH in the extracellular medium. Intravenous administration (i.v.) of AZD-PDPA NPs at a very low dose in TC-1 and B16F10 melanoma animal models showed an enhanced tumor growth inhibition (1.5-fold) over the oral administration of free AZ3965 at the recommended dose (>200 times the i.v. dose within the AZD-PDPA NPs), reducing cardiac and liver toxicities.

2.4. Carbonic anhydrases (CAs) inhibition

Carbonic anhydrases (CAs) are zinc metalloproteinases used by the cells to eliminate protons and CO₂. This elimination is especially important in cancer where there is an accumulation of both H⁺ and CO₂ due to the enhanced glucose metabolism. Overexpression of several CAs has been observed in cancer, specifically CA9 and CA12. CA9 expression is induced by HIF1 and blocking its activity leads to tumor growth inhibition⁴⁹ (Fig. 4A).

These high expression levels of CA9 are reflected in the data found at the COSMIC database⁴¹, where CA9 is found overexpressed in a third of upper aerodigestive tract and ovary cancers (Table 4), but also, in the GEO profile dataset⁵⁰, CA9 overexpression is observed in studies analyzing cervical, squamous lung and metastatic prostate cancer. Moreover, there are few genomic studies of CA9 in kidney cancer, where its importance has been established in several individual studies⁵¹. In addition, other CAs, such as CA5B and CA10, are overexpressed in adrenal gland and ovary tumors, respectively (Table 4).

Several inhibitors aiming to block CAs (CAIs) have been developed. Among them, several immunotherapy approaches against CA9 have reached as far as phase III clinical trials and might be the first cancer therapies targeting proton transporters to reach the clinical practice⁷². Moreover, recent publications have shown the effectiveness of sulfonamide CAIs (Fig. 4B), like the classical acetazolamide and dorzolamide, or the compounds SLC-0111 and indisulam that have reached phase II clinical trials³₂,⁴₂,⁴⁷,⁵². Some authors have used CA9 as therapeutic target to achieve a selective delivery of chemotherapeutic agents toward cancer cells by using conjugates (Table S1). Krall et al.⁵³ reported the first small molecule–drug conjugate to specifically deliver cytotoxic drugs to tumors overexpressing CA9. They used 5-amino-1,3,4-thiadiazole-2-sulfonamide (CL 5343), an acetazolamide derivative, as CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells. The authors showed the efficient tumor accumulation of CL 5343-fluorescent dye conjugates (13.4% of injected dose per gram of tissue, % ID/g, in 1 h) when applied to mice bearing subcutaneous tumors. Moreover, a non-toxic dose of 70 nmol of CL5343-maytansinoid conjugates showed a potent antitumor activity in those mice, compared to the standard treatment of kidney cancer with sunitinib and sorafenib. In a similar approach, Cazzamalli et al.⁵⁴ reported acetazolamide-monomethyl auristatin E conjugates with a potent antitumor activity in mice bearing SKRC52
renal carcinomas. Among different dipeptide linkers analyzed, valine–alanine and valine-citrulline showed the best stability in vitro (half-life of 23 and 11.2 h, respectively) and antitumor efficacy in vivo. Likewise, Marks et al. synthesized a conjugate for the targeted delivery of the cytotoxic tubulysin B towards CA9 expressing tumor cells. To do that, they used the CA9 inhibitor fluoro-benzosulfonamide (CAL) previously reported by Dudutiene et al. that possessed the best specificity and affinity values for CA9 of all the inhibitors tested by the authors. The CAL-fluorescein isothiocyanate (FITC) conjugates showed a potent binding capacity to the cell membrane of HT29, SKRC52 and AS49 CA9 expressing cancer cells. In addition, these authors

| Cancer            | MCT1 | MCT2 | MCT3 | MCT4 | MCT5 | MCT6 | MCT7 | MCT8 | MCT9 | MCT10 | MCT11 | MCT12 | MCT13 | MCT14 |
|-------------------|------|------|------|------|------|------|------|------|------|-------|-------|-------|-------|-------|
| Adrenal gland     | 1.27 | 1.27 | 1.27 | 5.06 | 3.8  | 56.96| 7.59 | 12.66| 5.06 | 12.66 | 3.8   | 56.96 | 7.59 | 12.66 |
| Breast            | 1.27 | 2.26 | 0.82 | 2.36 | 4.98 | 6.61 | 0.27 | 6.34 | 8.97 | 5.89  | 0.36  | 2.54  | 3.26 | 6.52  |
| CNS               | 3.01 | 2.87 | 1.87 | 2.15 | 3.16 | 5.31 | 1.29 | 4.88 | 3.01 | 6.46  | 5.88  | 5.45  | 5.45  | 4.59  |
| Cervix            | 1.3  | 4.89 | 5.21 | 1.95 | 1.95 | 2.28 | 2.93 | 0.33 | 3.58 | 8.14  | 1.95  | 4.23  | 6.19  | 4.56  |
| Endometrium       | 3.32 | 5.65 | 7.81 | 2.49 | 2.49 | 3.16 | 3.65 | 5.32 | 4.82 | 9.47  | 3.65  | 11.63 | 3.49  | 5.65  |
| Hematop. & Lymph. | 4.98 | 4.52 | 2.71 | 4.07 | 8.6  | 1.81 | 3.17 | 11.31| 8.14 | 4.62  | 8.14  | 7.24  | 2.58  | 5.88  |
| Kidney            | 4.17 | 1.17 | 1.15 | 4.5  | 4.5  | 7.83 | 5.67 | 0.67 | 3.67 | 1.5   | 1.17  | 5     | 5     | 2.83  |
| Large intestine   | 4.26 | 3.11 | 12.79| 7.05 | 3.61 | 3.11 | 1.64 | 1.64 | 3.93 | 5.08  | 3.28  | 5.41  | 3.44  | 12.79 |
| Liver             | 1.07 | 4.29 | 0.88 | 4.56 | 1.88 | 6.97 | 4.02 | 5.36 | 1.34 | 4.83  | 2.14  | 2.95  | 4.29  | 6.7   |
| Lung              | 2.75 | 2.65 | 3.83 | 1.47 | 2.45 | 3.73 | 0.39 | 4.32 | 4.22 | 4.61  | 9.13  | 4.12  | 8.73  | 3.73  |
| Oesophagus        | 8.8  | 8    | 4    | 10.4 | 0.8  | 9.6  | 14.4 | 8.8  | n/a  | 6.4   | 8.8   | 2.4   | 8.8   | 35.2 |
| Ovary             | 6.02 | 2.26 | 4.51 | 1.88 | 1.5  | 1.5  | 8.27 | 6.39 | 14.29| 28.95 | 24.81 | 3.01  | 3.76  | 2.26  |
| Pancreas          | 1.12 | 3.91 | 2.79 | 1.12 | 4.47 | 3.35 | 1.68 | 11.12| 3.01 | 14.53 | 3.45  | 2.49  | 4.98  | 4.29  |
| Prostate          | 2.41 | 4.22 | 1    | 2.81 | 4.82 | n/a  | 1.61 | 6.83 | 6.22 | 5.42  | 1     | 5.42  | 4.02  | 4.29  |
| Skin              | 1.69 | 2.75 | 3.81 | 2.96 | 3.59 | 3.17 | 1.9  | 2.54 | 5.5  | 4.86  | 2.11 | 4.02 | 6.55  | 8.67  |
| Soft tissue       | 1.52 | 2.66 | 0.38 | 7.22 | 4.56 | 12.93| 0.76 | 5.7  | 3.04 | 4.94  | 1.9   | 2.28 | 4.56  | 0.76  |
| Stomach           | 5.61 | 5.61 | 4.56 | 6.67 | 1.05 | 7.72 | 3.86 | 12.36| 3.86 | 11.33| 6.32  | 11.93| 6.32  | 10.88 |
| Thyroid           | 0.39 | 0.19 | 0.78 | 4.87 | 2.53 | 3.12 | 1.56 | 7.41 | 0.19 | 4.68  | 1.56 | 6.04 | 5.85  | 2.73  |
| Upper aerodig. tract | 1.34 | 11.88| 2.87 | 0.57 | 3.28 | 5.56 | 3.45 | 2.49 | 3.64 | 33.52 | 4.21 | 5.56 | 4.41  | 4.02  |
| Urinary tract     | 1.72 | 1.72 | 4.41 | 7.11 | 0.98 | 4.66 | 0.74 | 0.98 | 3.68 | 4.9   | 3.92 | 6.37 | 3.43  | 4.41  |

Overexpression levels of the carbonic anhydrase (CA) family members in cancer affecting several tissues. Asterisks: also downregulated in some patients. * (5%–10%), ** (10%–15%). Overexpression >20% in bold letters. n/a, not available.
demonstrated the efficacy of CAL-tubulysin B conjugates (with self-immolative linkers) in killing transfected HEK293 cells (IC_{50} = 1.05 nmol/L) and reducing HT29 tumor xenografts in mice and A549 tumor xenografts in mouse with no toxicity. Lv et al. reported the synthesis of CA9 inhibitor-containing conjugates, with a PEG linker, to the specific delivery of tubulysin B or technetium-99 m to CA9 expressing cancer cells. The authors chose the potent CA9 inhibitor polyamino-polycarboxylamido aromatic sulfonamide, previously reported by Rami et al. Bio-distribution studies in mice bearing HT-29 tumor xenografts showed that the CA9 inhibitor-technetium-99 m conjugates markedly accumulate in tumor with a low % ID/g of 1.4 ± 0.4 after 4 h. The CA9 inhibitor—tubulysin B conjugates showed an IC_{50} value of 4.4 nmol/L in HT-29 cancer cells with no toxicity up to concentrations of 1 μmol/L, and an absence of growth of the tumor in mice bearing HT-29 xenografts after the administration of the non-toxic dose of 2 μmol/kg.

Apart from the CA9 ligand—drug conjugates, there are other carriers that can specifically deliver cytotoxic drugs to CA9 expressing cancer cells (Table S1). Janioniene et al. developed 185 nm porous silicon nanoparticles (NPs) functionalized with VD1-4-2, a sulfonamidic fluorescent CA inhibitor (CAI) synthesized by the authors, for the targeted and pH-sensitive delivery of doxorubicin (DOX) to MCF-7 breast cancer cells. The system showed a potent affinity, specificity and killing capacity for CA9 expressing MCF-7 cells.

Shabana et al. described for the first time PEGylated CAI-conjugated Au-NPs that target CA9 isoform for delivery of DOX to hypoxic tumor microenvironments (Fig. 5). In order to selectively reach the transmembranal CA9 isoform, these authors combined membrane-impermeable oligoethyleneglycol (3 units) or PEGylated (with a low molecular weight of 2000) CA9 inhibitor conjugates, as targeting ligands, with Au-NPs, which are also impermeable to the plasma membrane. The optimized formulation, which contained the best ligand density and the maximum drug loading in the surface of the particles to maintain colloidal stability, was very effective against HT-29 tumor cells under hypoxic conditions. Moreover, this formulation enhanced 2.5 times the intratumoral delivery of DOX when compared with non-targeted formulations or free DOX, minimizing chemoresistance. In order to achieve a selective delivery of DOX to the lysosomes of cancer cells, these authors studied the influence of the length of the spacer between the particles and the ligands to avoid the nonspecific uptake of the CAI-conjugated Au-NPs under hypoxic conditions. The Au-NPs with PEG spacers avoided the unspecific uptake observed in Au-NPs or CAI-conjugated Au-NPs with short spacers under normoxic or hypoxic conditions. Based on that, they showed the influence of the level of oxygen on the uptake of CAI-conjugated Au-NPs when PEG spacers were used, observing a low uptake under normoxic conditions and a high CA9-mediated uptake under hypoxia. The optimum conjugation of DOX to the surface of the Au-NPs was achieved by a conjugate of DOX with dithiodipropionic acid (DTDP), as anchoring ligand, and hydrazone, as pH-dependent linker. This synthesis strategy led to a pH-dependent release profile of DOX, with a controlled release of less than 25% at pH 7.4 after 24 h and a burst release of 80% and 98% after 4 and 24 h, respectively, at an acidic pH of 5.5.

Alsaab et al. reported an 159.5 nm acetazolamide-conjugated micellar nano-formulation based on vitamin-E-α-D-tocopherol (TPGS) and styrene maleic anhydride (SMA) to specifically deliver the apoptosis inducer CFM 4.16, in combination with sorafenib, to the hypoxic core of the tumor, in order to overcome the MDR in renal cell carcinoma (RCC). The authors showed the capacity of the formulation to produce a large decrease in cell viability of everolimus-resistant (Ervm-res) A498 renal cancer cells (IC_{50} = 850 nmol/L) compared to free everolimus (IC_{50} >10 μmol/L) and sorafenib (IC_{50} = 9 μmol/L), showing a synergistic killing effect when combined with low doses of sorafenib. In addition, they demonstrated the great hypoxia-mediated penetration of CA9-targeted TPGS-SMA oligomers in the core of...
Evrm-res A498 RCC cells-based tumor spheroids and tumors of mice bearing subcutaneous Evrm-res A498 RCC (3-fold compared to control and 2-fold compared to peripheral tissue of tumor) by near infrared imaging. Moreover, they demonstrated the enhanced antitumor capacity of the combination in combination with sorafenib, in Evrm-res A498 tumors, compared to the treatment with the free drugs, with no toxicity in liver and kidney.

Recently, Tatiparti et al.\(^{52,62}\) reported the targeted delivery of 3,4-difluorobenzyliden curcumin (CDF)\(^{52}\) or paclitaxel (PTX)\(^{62}\) to CA9 expressing MDA-MB-231 and MDA-MB-468 triple negative breast cancer (TNBC) cells by means of acetazolamide-conjugated albumin NPs, which were prepared by the desolvation/coacervation method and the copper-free click chemistry. According to the cytotoxic studies, the CDF or PTX-loaded systems showed an enhanced efficacy in killing TNBC cell lines (IC\(_{50}\) of 31.13 or 1 \(\mu\)mol/L of CDF or PTX for MDA-MB-231 and 3.78 or 0.5 \(\mu\)mol/L of CDF or PTX for MDA-MB-468) compared to the non-targeted system and the free cytotoxic drugs, being the percentage of living cells up to 2.8 times lower in the case of hypoxic conditions with respect to normoxic conditions\(^{2,62}\). The authors explained these results by an enhanced hypoxia-mediated internalization of the acetazolamide-conjugated NPs in CA9 overexpressing cells, which was demonstrated by fluorescent cell uptake studies, and the enhanced apoptotic capacity of the CA9-targeted system with respect to the non-targeted one\(^{52,62}\). In addition, the injection of the acetazolamide-conjugated albumin NPs, modified with a near infrared dye, into mice bearing TNBC patient-derived tumor xenografts showed their specific accumulation in the tumor, with a reduced uptake in the spleen and the liver\(^{52}\).

The high affinity of the classic CAIs for all the different isoforms of the CAs has reduced their advance to clinical use since they produce inhibition of CAs in normal cells and not only in the targeted CAs\(^{20,67}\). Thus, to avoid the toxic side effects of most of these inhibitors, new approaches have been developed to design more selective inhibitors in order to reduce the deleterious effects to the normal tissue. CAs are located and distributed differently depending on their isoform, being in particular CA9 and CA12 the only membrane-bound isoforms that generate their catalytic activity in the extracellular milieu\(^{11}\). Taking advantage of this fact, several authors have designed different strategies to avoid the passage of CAIs throughout the plasmatic membrane, preventing their interaction with the intracellular CA isoforms.

In this regard, gold nanoparticles (Au-NPs) have played an important role. Stiti et al.\(^{52,62}\) synthesized CAI-coated Au-NPs with an average particle size of 3.3 nm and non-permeable characteristics with respect to the plasmatic membrane. They showed promising comparative data about several CAIs, the standard acetazolamide, the sulfonamide 3a and the sulfonamide-3a-coated Au-NPs. As controls, they used a sulfonamide derivative with no CAs inhibition, either isolated or coating the Au-NPs, and non-coated Au-NPs, showing no inhibition of any of the isoforms. Acetazolamide showed inhibition of the CA2 and 9 isoforms, however, the sulfonamide 3a, either isolated or coating the Au-NPs, showed a good selectivity in the inhibition of the CA9 isoform over CA1 and 2, presenting the best selectivity when coating the Au-NPs due to their membrane-impermeable characteristics. New work on this formulations\(^{64}\) improved the synthesis route of the CAI-coated Au-NPs by a one-pot modified citrate method to achieve dispersibility and stability in aqueous media, maintaining the selectively to inhibit the transmembrane isoforms CA9 and 12 over the cytosolic CA1 and 2. This new approach achieved very stable aqueous colloidal suspensions, where the CAI coating of the Au-NPs, a sulfonamide derivative, played an important role in the stabilization of the Au-NPs when increasing the ionic strength. The authors concluded that the inhibition is only due to the interaction between the sulfonamide derivative and the CAs, contributing the Au-NPs in the selectivity towards the membrane-bound isoforms because of the impermeability of the particles to the plasmatic membrane.

Ratto et al.\(^{65}\) proposed for the first time the use of plasmonic gold nanorods with dog-bone shapes and sulfonamide derivatives as a combined therapy in cancer to achieve a selective inhibition of the transmembrane CA isoforms and near infrared (NIR) hyperthermia. The authors showed the \textit{in vitro} specific accumulation of the CAI-conjugated gold nanoparticles in human colorectal carcinoma HCT116 and human mammary adenocarcinoma MDA-MB-231 cells under hypoxic conditions. The incorporation of CAIs to the gold nanorods produced a clear cytotoxic effect that is directly related to the inhibition of the transmembrane CAs. In fact, cytotoxicity was stronger in the MDA cells than in the HCT, since the mammary cells express CA9 only while the HCT116 cells show activity of the CA9 and 12 isoforms. The specific inhibition of the CA9 and 12 by the CAIs-conjugated gold nanorods was confirmed by a partial alkalinization of the extracellular environment. A large reduction in cellular proliferation was observed, but induction of apoptosis was similar to the administration of the CAIs alone. When the CAIs-conjugated gold nanorods were excited at the low power density of 50 W/cm\(^2\), the combined effect of optical hyperthermia and CAs inhibition was lethal to the cells under hypoxic conditions. As mentioned before\(^{65}\), in addition to the generation of hyperthermia, the gold nanorods added impermeability to the plasmatic membrane to get a selective and

![Figure 7](https://example.com/figure7.png)

\[\text{Figure 7} \quad \text{Mechanisms of action of pH-sensitive nanocarriers.} \]

Reprinted from Ref. 92. Copyright © 2015 with permission from Elsevier.
targeted inhibition of the membrane-bound CA isoforms in the cancer cells.

3. Nanocarriers for intracellular proton release

An innovative approach to reverse the anomalous pH gradient in tumors is the direct generation of intracellular acidification by proton-caged carriers that may initiate an apoptotic pathway in cancerous cells remotely via UV irradiation. A caged compound is a molecule that is trapped in an inactive form, normally by a chemical conjugation with light-sensitive linkers, and is released as an active form when irradiated with near-UV light that break the spacer, removing the protecting group\(^6\). This technology has been used in cancer therapy to achieve a targeted delivery of anticancer drugs, like 5-fluorouracil (5-FU), to avoid the toxicity of the drug outside the tumor. Agasti et al. \(^7\) reported 2 nm 5-FU-conjugated Au-NPs, using ortho-nitrobenzyl (ONB) as the photo-cleavable linker between the drug and the surface of the particles. These authors monitored the 5-FU controlled release from the Au-NPs when irradiated with UV-light (365 nm) that cleaved the ONB. Drug release was only observed under irradiation, with a maximum value after 10 min. Thus, the 5-FU-conjugated Au-NPs did not produce cytoxicity in MCF-7 cells in the dark, but when particles were irradiated for 20 min a strong decrease in cell viability was observed. The authors demonstrated the promising properties of Au-NPs as carriers and cages of anticancer drugs that are inactive when linked to the particles and produced the required therapeutic effect when released after exposure to UV-light.

The majority of the reported caged compounds are built with a 2-nitro-benzyl or 2-nitro-phenyl linker and one proton is released when these conjugates are irradiated with UV-light to liberate the trapped molecule in their active form, generating a rapid acidification\(^8\). Taking advantage of these facts, some compounds that include photo-sensitive moieties, such as 2-nitro-benzyl or 2-nitro-phenyl, have recently been developed as proton caged carriers (PCC) to generate photo-inducible intracellular acidification. This is achieved by means of protons that are released because of the ionization of nitronic acid, the primary photochemical product that is generated by the photolysis of the 2-nitro benzyl or 2-nitro-phenyl-based compounds\(^9\). Furthermore, these PCC are normally modified to be conjugated to different nanocarriers in order to facilitate their internalization and thus generate the intracellular acidification.

Carbone et al. \(^6\) demonstrated by FTIR spectromicroscopy the possibility of reducing the pH of NIH 3T3 fibroblast cells by using the synthetic PCC 1-(2-nitrophenyl)-ethylhexadecyl sulfonate (HDNS) and UV irradiation at 275–375 nm. Based on this compound, they synthesized a new PCC, the disulfanediyldinonane-9,1-diylbis[[1-(2-nitrophenyl)ethoxy]sulfonyl] carbamate (NESS-deca) that contains the light-sensitive o-nitrobenzoic ester but also includes sulfur groups to allow its conjugation to the surface of 22 nm Au-NPs\(^7\). HEK-293 cells were incubated with free NESS-deca or NESS-deca-conjugated AuNPs and, following the CO\(_2\) signal by FTIR spectroscopy they monitored intracellular acidification after UV irradiation. The conjugation of NESS-deca to the AuNPs enhanced 400 times their acidification capacity inside the cells due to the improved cellular uptake of the PCC because of the vectorial properties of AuNPs.

In a similar approach, Sabbatella et al. \(^7\) synthesized the di-sulfanediyldienesane-6,1-diylbis[1-(2-nitrophenyl)ethoxy]sulfonyl]carbamate (NESS-hepta) and the above-mentioned NESS-deca. Both compounds, which possessed the o-nitrobenzyol photo-cleavable group to generate acidification and the disulphide group to be conjugated to 22 nm Au-NPs, were characterized by FTIR and \(^1\)H NMR. The acidification capacity of both compounds was assessed by FTIR spectroscopy after UV-irradiation and their conjugation ability to Au-NPs by thermo-gravimetric analysis (TGA).

Gdovin et al. \(^1\) used the PCC o-nitrobenzaldehyde (NBA) and UV irradiation to generate a significant intracellular acidity that induced apoptosis of different cell lines in 2 h. Thus, the reduction of pH induced an 85% apoptotic rate in the non-cancerous rat pheochromocytoma PC12 cells and a 98% rate in breast cancer MCF-7 cells. The apoptosis values in MCF-7 cells under UV light or NBA alone were significantly lower (7.1% or 2.3%) than a combination of NBA and UV-based irradiation. Moreover, they described that NBA diffuses easily into the cell and remains trapped and inactive until irradiated with UV-light, at which time it generates intracellular acidification, independently of the cell line, being this combination effective in inducing apoptosis in non-cancerous PC12 cells, MCF-7 and MDA-MB-231 human breast cancer cell lines, BxPC-3 human pancreatic cancer cell line and LNCaP human prostate cancer cell line. In vivo, they performed the treatment of triple negative breast cancer in mice with NBA and UV-irradiation, resulting in a significant reduction of the tumor volume and growth, as well as an increase in the survival of the animals. In addition, these authors made an important contribution to this therapeutic strategy by conjugating NBA to up-converting NPs (UPNPs) in order to solve the difficulty of reaching deep tissue regions with near UV irradiation (350–550 nm). UPNPs are able to absorb low-energy near infrared (NIR) light at 980 nm that easily penetrate in biological tissues without causing damage and emit the high-energy photons at 350–400 nm that are necessary to produce the cleavage of NBA and generate the intracellular acidification (Fig. 6). The reported NBA-conjugated UPNPs produced similar intracellular acidification and apoptotic cell death (91.5%) than using NBA and UV-irradiation and can be functionalized to target cancer-specific receptors. Using a similar approach, Zhou et al. \(^2\) recently reported the assembly of poly (amidoamine) (PAMAM) dendrimers on the surface of polyacrylic acid (PAA)-coated UPNPs to include in the system the PCC capacity of NBA. These 80 nm NBA-PAMAM-PAA-UPNPs were able to release hydrogen ions to generate intracellular acidification in HN3T3 cells and HepG2 cancer cells by the emission of photons of 365 nm with irradiation at 980 nm.

4. pH-sensitive drug nanocarriers

The main drawbacks of chemotherapy are the growth inhibition and unspecific damage on normal cells, which produces important side effects in the patients\(^3\). One of the most frequent approach to maintain chemotherapeutic drugs inactive and apart from blood circulation until located in the tumor microenvironment, is the use of nano-scale carriers.

In this section, we describe the use of the reverse pH gradient and the consequent acidic extracellular microenvironment in tumors to generate a focalized delivery of anticancer drugs. Several approaches use the acidic extracellular pH (pHe) to induce a pH-dependent drug release (Fig. 7A) by:

(1) The destabilization of the structure of drug-loaded nanocarriers, which are elaborated including pH-sensitive moieties, like poly (histidine), poly (aspartic acid-graft-
An approach frequently used has been to include pH-sensitive blocks, mainly poly (histidine) and poly (beta-aminoester) (PAE), in the structure of the polymers that will later form part of the delivery systems. When the pH-sensitive drug carrier reaches the tumor, the slightly acidic pH₆₅ (6.5—7.0) destabilizes the polymers causing the release of the content of the carrier.

This strategy was used for the first time by Bae and collaborators, who developed polymeric micelles based on poly (l-histidine)-b-poly (ethylene glycol) and poly (l-lactide)-b-poly (ethylene glycol). Poly (histidine) pH-sensitive blocks generated the destabilization of the micelles under acidic conditions due to reversible transitions from a hydrophobic state at pH values above 7.4 to a hydrophilic state by protonation of amine groups at pH values below 7.0⁷⁶. Varying the ratio between both polymers, these authors were able to optimize the sensitivity of the micelles. A 25% (w/w) of poly (l-lactide)-b-poly (ethylene glycol) led to the destabilization of the micelles at pH 6.8, being stable at pH values ranged between 7.0 and 7.4. Using this formulation they observed an increase in the cumulative release of Adriamycin from 32% (w/w) at pH of 7.0—70% (w/w) at pH of 6.8⁷⁵. Moreover, they were able to incorporate DOX in these pH-sensitive micelles by hydrophobic interactions between the drug and the hydrophobic poly (histidine) blocks when deprotonated at pH 7.4. Using MCF-7 breast cancer cells xenografts in mice, these authors observed a destabilization of the micelles and a release of DOX at the acidic pH₆₅ that led to a significant reduction of the tumor volume and growth compared to non-pH-sensitive micelles or free DOX controls⁷⁵. This laboratory also synthesized “flower-like” 80 nm DOX-loaded poly (l-lactic acid)-b-poly (ethylene glycol)-b-poly (l-histidine) micelles to avoid the destabilization of the micelles at acidic pH and produce a pH-induced swelling that increased the size of micelles up to 580 nm at pH 6.8 that generated the release of 60% (w/w) of DOX after 24 h (from only a 32% at pH 7.4). The authors demonstrated the pH-dependent cytotoxicity of the “flower-like” DOX-loaded micelles in MCF-7 cells, showing a reduction of cell viability from 87% at pH of 7.4—40% at pH of 6.8 and 26% at pH of 6.0, meanwhile free DOX cell viability was <20% over the entire pH range⁷⁵. In addition, this group has described the preparation of 140 nm methoxy-poly (ethylene glycol)-b-poly (l-histidine)₂ polymersomes with a good proton buffering capacity (between the pH values 7.4 and 5.0) and the capacity to fuse with the endolysosomal membranes of cells, which means that this system may escape from endosomes and lysosomes. At the pH range between 9.0 and 7.4 the polymersomes exhibited a stable spherical structure that was transformed to a branched and elongated structure with an equivalent hydrodynamic diameter of 400 nm at pH 6.8, which was produced by a large reduction in the hydrophobicity of poly (histidine) below the slightly acidic pH₆₅. This change in the structure of the polymersomes at pH 6.8 generated a very significant pH-dependent modification in the release profile of 5 (6)-carboxyfluorescein from these systems, increasing the cumulative release from 30% at pH 7.4 after 72 h to the complete release of the dye at pH 6.8 after only 4 h⁷⁷.

Johnson and coworkers⁷⁸ described the development of biocompatible hybrid polymeric vesicles based on poly (ethylene glycol) methyl ether acrylate, poly (l-lysine) and poly (l-histidine) blocks for the pH-induced intracellular delivery of DOX. As described above, poly (histidine) blocks that swell at the acidic pH₆₅ in tumors were responsible for the structural destabilization of the vesicles, provoking a pH-induced release of the cytotoxic drug (80% at pH 5.5 after 72 h). These authors showed the pH-dependent cytotoxic response and cellular uptake of the hybrid micelles into CT26 murine cancer cells with a maximum peak at pH 5.5.
In addition of polymeric micelles, several authors have been reported the use of the poly (l-histidine) blocks to generate NPs as pH-sensitive drug delivery systems. Hwang et al.79 described the utilization of dextran-b-poly (l-histidine) copolymer to manufacture DOX-loaded NPs by the nanoprecipitation dialysis method. They reported that, at the acidic tumor pH, the NPs swelled and released their cargo, with a pH-dependent controlled release of DOX, which doubled at acidic pH values with respect to pH 7.4. These authors showed a decrease in the viability of HuCC-T1 cholangiocarcinoma cells when incubated at the acidic tumoral pH, with the DOX-loaded NPs, while free DOX showed an enhanced interaction and toxicity in the same cells at basic pH.

Oh’s research group80,81 described DOX-loaded self-assembled micelles based on poly (aspartic acid-g-imidazole)-b-poly (ethylene glycol) copolymer, with an isoelectric point of 6.5 and a buffering capacity between the pH values 7.5 and 5.7 as an alternative to poly (histidine) blocks. Since these micelles destabilize at pH < 7.0 and decompose at pH 6.0, these carriers showed a pH-dependent release of DOX below pH 6.5, with a cumulative release of 60% at this pH and a constant value of 37.6% within the pH range 7.0–8.0. This fact explained the absence of cytotoxicity on MCF-7 cells of the DOX-loaded micelles at that pH range and a high cytotoxicity at acidic pH (IC50 of 0.32 and 0.125 µM at pH 6.5 and 6.0, respectively), with similar values of cell viability to those observed with the free drug. Moreover, in vivo, Cy5.5-labelled micelles specifically accumulated in mice bearing subcutaneous MCF-7 cells tumors, with no accumulation in the liver and the kidneys.

Ko and collaborators82 reported DOX-loaded self-assembled methyl ether poly (ethylene glycol) (mPEG)-poly (beta-amino ester) polymeric micelles. The system showed a micellization/demcellization pH of 6.8 due to the presence of the pH-sensitive block, poly (beta-amino ester), which led to a fast release of DOX (>71% in 6 h) at pH of 6.4 with no significant release of the drug at pH 7.4 after 24 h (apart from the initial burst release of 17%). The authors showed an enhanced uptake of the DOX contained in the micelles in B16F10 melanoma cells at pH 6.4, with a cell distribution similar to the free drug. Moreover, these polymeric micelles (at 2 mg of DOX per kg) reduced the tumor volume in mice bearing subcutaneous B16F10 tumors by 72.69% from a cumulative release of 10.4% at pH 7.4) and induce their release at the acidic pH in tumors. They loaded DOX inside the nano-channels of silica NPs, being “nanogates” that are opened with the slightly acidic pH in tumors. They loaded DOX inside the nano-channels of the NPs that was released in a controlled way only under acidic pH, with a significantly enhanced release at the highly acidic conditions (pH = 5.0) in the intracellular organelles after endocytic uptake. Chen et al.83 coated DOX-loadedPEGylated silica NPs with the pH-sensitive “gatekeeper” poly (2-pentamethyleniminio) ethyl methacrylate (PEEMA) to close the pores of the NPs at physiological pH, avoiding the release of DOX during blood circulation (cumulative release of less than 15% at pH 7.4). At pH 6.5 the pores opened, releasing the cytotoxic drug (68%) due to the protonation of PEEMA that reversed the charge of the NPs from negative (−22.6 mV) to positive (+69.4 mV), which facilitated cellular DOX uptake. These NPs exhibited an IC50 value on HeLa cells of 21.75 µg/mL. Recently, Chen et al.84 described the coating of DOX-loaded silica NPs with chitosan crosslinked with N,N-bis(acryloyl)cystamine (BAC) by disulfide bonds to protect the cytotoxic drug during blood circulation (cumulative release of 10.4% at pH 7.4) and induce their release at acidic pH.

In another attempt to generate pH-sensitive micelles carrying a cytotoxic drug, Lee et al.85 introduced 3-diethylaminopropyl (DEAP), as pH-sensitive moiety, and synthesized Y-shape chlorin e6 (Ce6)-loaded micelles composed of one methoxy-poly (ethylene glycol) block and two poly (l-lysine)-DEAP blocks. These micelles showed a “worm-like” structure at pH 7.4 that can be destabilized at a pH 6.8 due to the protonation of the DEAP moiety, allowing the pH-induced release of Ce6 [32% (w/w)] at pH of 7.4 and 70% (w/w) at pH of 6.0 after 24 h] and an enhanced cellular uptake of the micelles in KB cells at the pH range of 6.0–6.8. Both events generated an increase in the phototoxicity of the formulation on KB cells, at pH values below 7.0 and using photosensitizing agent concentrations ranging from 0.1 to 10 µg/mL. In vivo, the Ce6-loaded micelles showed an enhanced tumor accumulation and a 5.2-fold tumor volume reduction compared to the free drug in nude mice bearing KB tumors.

Wang et al.86 used methoxy poly (ethylene glycol)-b-poly (N-e-(1-carboxy-cis-cyclohexene)-2-carboxyl)-l-lysine) (mPEG-b-PCLL), as a pH-sensitive complex, to synthesize 89.6 nm DOX-loaded mPEG-b-PCLL micelles with a stable structure at pH 7.4 that swelled (up to 862 nm of hydrodynamic diameter after 24 h) and then disassembled at pH 6.8, being the process faster at pH 5.5. However, these micelles only showed a significant difference in the release profile of DOX at the intracellular pH of 5.5. Despite this, the mPEG-b-PCLL micelles showed an enhanced tumor growth inhibition in mice bearing H22 hepatoma cells (68.1%) compared to the free drug (47%) after 17 days, inducing larger necrotic and apoptotic areas (~30%) and reduced toxicity.

4.1.2. Gate opening in the nanocarriers
The acidic pH of the tumor microenvironment can be used to induce molecular changes in the coating of porous nanocarriers that produce the opening of their pores with the consequent release of their cargo. This can be achieved through alterations in the structure/characteristics of the compounds of the NPs’ coating or by the complete removal of this covering. In this section we will explain the most frequent approaches to induce a drug release process by a pH-dependent gate opening (Supporting Information Table S3).

Bilalis et al.87 reported an innovative use for the poly (l-histidine) group as a pH-sensitive shell of the pores of mesoporous silica NPs, being “nanogates” that are opened with the slightly acidic pH in tumors. They loaded DOX inside the nano-channels of the NPs that was released in a controlled way only under acidic pH, with a significantly enhanced release at the highly acidic conditions (pH = 5.0) in the intracellular organelles after endocytic uptake. These NPs exhibited an IC50 value on HeLa cells of 21.75 µg/mL. Recently, Chen et al.88 described the coating of DOX-loaded silica NPs with chitosan crosslinked with N,N-bis(acryloyl)cystamine (BAC) by disulfide bonds to protect the cytotoxic drug during blood circulation (cumulative release of 10.4% at pH 7.4) and induce their release at acidic pH.
showed at pH 6.8 an enhanced cellular uptake because of their removal of this polymer from the surface of the cisplatin (IV) PEG-(PAH/DMMA) from negative to positive, which led to the reduced to 6.8, the hydrolysis of DMMA modified the charge of (ethylene glycol)-poly (allyamine hydrochloride)/DMMA (PEG-conjugated carbon dots with the negatively charged poly nanocarrier showed a potent cytotoxicity at pH 6.5 (75% of viable zone linker was cleavage at pH 5.5, releasing the cytotoxic drug endocytosis, using the HA as active targeting ligand, the hydrazone linker. At the tumor pH e, poly (histidine) chains coated with a conjugate of DOX and hyaluronic acid (HA), using the hydrazone linker. At the tumor pHL, poly (histidine) chains protonated, provoking the release of the R848 to regulate the immune response. Once the NPs were uptake by CD44-mediated endocytosis, using the HA as active targeting ligand, the hydrazone linker was cleavage at pH 5.5, releasing the cytotoxic drug (DOX) in the intracellular region and reducing cell viability of breast cancer cells. This dual system showed tumor growth inhibition in 4T1 tumor-bearing mice.

To achieve a regulated release of DOX, Wu et al. incorporated DMMA to poly (0,1-lactide)-b-poly (2-aminoethyl methacrylate) (PLA-b-PAEMA) to obtain PLA-b-PAEMA/DMMA block copolymers and then self-assembled NPs with a core of PLA and a shell of PAEMA/DMMA with charge modification properties by the hydrolysis of DMMA at pHL (the NPs have a negative charge at pH 7.4 but positive at pH 6.5). Positively charge DOX were included into the negatively charged NPs (−18.3 mV) at physiological pH due to electrostatic interactions (with a small cumulative release of around 20%) and released at pH of 6.5 (cumulative release of 75%) because of the hydrolysis of DMMA, which confers a positive charge to the NPs (+4.4 mV) breaking the electrostatic interactions between the drug and the carrier. In HeLa cells, the DOX-loaded PLA-b-PAEMA/DMMA NPs demonstrated an enhanced intracellular distribution and the nanocarrier showed a potent cytotoxicity at pH 6.5 (75% of viable cells at a nanocarrier concentration of 6.25 µg/mL and 15% at 100 µg/mL). Using a similar strategy, Meng et al. described the complexity of the positively charged cisplatin (IV) prodrug-conjugated carbon dots with the negatively charged poly (ethylene glycol)-poly (allyamine hydrochloride)/DMMA (PEG-(PAH/DMMA) by electrostatic interactions. When the pH was reduced to 6.8, the hydrolysis of DMMA modified the charge of PEG-(PAH/DMMA) from negative to positive, which led to the removal of this polymer from the surface of the cisplatin (IV) produg-conjugated carbon dots. In A2780 cancer cells, this system showed at pH 6.8 an enhanced cellular uptake because of their positive charge after the hydrolysis of DMMA and a potent cytotoxicity due to the release of the prodrug (cumulative release of more than 70% at pH 6.5 and 10 mmol/L of GSH) that was reduced to cisplatin. In vivo at a dose of 1.5 mg of platinum per kg of body weight a 9-fold tumor growth inhibition was achieved compared to controls, after 14 days of treatment in mice bearing subcutaneous cervix U14 xenografts, with no signs of toxicity to the animals.

4.2. Favoring the pH-dependent internalization of nanocarriers

In addition to their use for the pH-dependent release of cytotoxic drugs, pH-sensitive blocks have been also used to promote the internalization of nanocarriers by either mediating pH-induced modifications to the charge on the nanocarrier surface, or stimulating the active targeting function in the nanocarrier or removing the PEG chains when exposed to the pHL in tumors.

4.2.1. pH-induced surface charge modification

One of the approaches most frequently employed to enhance the internalization of the nanocarriers is to use the acidic tumoral environment to induce a change in the charge of these nanocarriers (Supporting Information Table S5). At a physiological pH the nanocarriers show a negatively charged surface, but protonation upon environment acidification near the tumors leads to a reversal in the charge that allows the internalization of the nanocarriers by the cancer cells.

Hu et al. combined a positively charged paclitaxel-loaded poly (-histidine)/polyethyleneimine-based micelles with the pH-sensitive negatively charged block α-methoxy ω-hydroxy poly (ethylene glycol)-b-polysulfadimethoxine (mPEG-b-PSDM) by electrostatic complexation to enhance their stability in blood at physiological pH. The protonation at pH 6.9 of the negatively charged PSDM, a sulfonamide derivative, led to the dissociation of mPEG-b-PSDM from the positively charged micelles, being the charge reversal from negative to positive completed at pH 6.6. As mentioned above (section 4.1.A), the inclusion of the poly (histidine) group in the micelles generated the pH-dependent release of paclitaxel (cumulative release of 10% at pH 7.4 and 70% at pH 6.6). The system showed an enhanced cellular uptake at pH 6.6 in MCF-7 and SKOV-3 cancer cells compared to the minimal non-specific uptake at pH of 7.4. Moreover, the authors demonstrated the potent cytotoxicity of the paclitaxel-loaded micelles in MCF-7 cells, with similar values of IC50 (37 ng/mL) than the free drug (24 ng/mL) at pH 6.6 and a reduced cytotoxicity at pH 7.4 (IC50 of 295 ng/mL). In vivo, this formulation exhibited a deep tumor penetration and a 2.2-fold tumor growth inhibition compared to the treatment with the free drug after 29 days in a mice MCF-7 model.

Ye et al. synthesized smart hybrid DOX-loaded NPs by the nanoprecipitation method. These NPs were composed of a PEGylated lipid shell, which provides the biocompatible and stealth character to the NPs, and a poly (histidine) core to facilitate both intracellular uptake and controlled drug release inside the cells after internalization in a pH-dependent two-phase process. A) A first phase at the pHL in tumors (6.5−7.0) with the movement of the poly (histidine) blocks to the surface due to the swelling of the NPs at this pH, which produces a partial release of the drug and a shift in the surface charge from negative to neutral or slightly positive that facilitates the intracellular uptake of the NPs. B) Once the NPs were internalized, in a second phase, there is a complete destabilization of the NPs at values of pH between 4.5

The reverse intra/extracellular pH in tumors and targeted nanocarriers 2257
and 6.5, producing the total release of the cargo of the NPs in the cytoplasm. In vivo, this drug delivery system increased the anti-tumor efficacy of free DOX in 4T1 tumor-bearing mice.

Du and co-workers99 modified poly (2-aminoethyl methacrylate hydrochloride) (PAMA) nanogels with DMMA to obtain DOX-loaded carriers with a pH-induced tunable surface charge from negative at physiological pH to positive at the slightly acidic pH$_e$ in tumors (pH = 6.8). The PAMA-DMMA nanogels possessed a negative charge during their circulation in blood, which avoids the interaction with the blood proteins, and a positive charge once in the tumor microenvironment at pH 6.8, which promotes their efficient intracellular uptake. Positively charged DOX was efficiently loaded to the negatively charged nanogels by electrostatic interactions at physiological pH and completely released at the acidic pH of the intracellular organelles (pH = 5.5) by electrostatic repulsion because of the positive charge of the nanogels from the pH$_e$. The authors showed a higher decrease in cell viability in MDA-MB-435s cells when cultured with this formulation with respect to PAMA nanogels without the acid-cleavable linker, promoting the intracellular delivery of the siRNA. Reprinted with permission from Ref. 106. Copyright © 2012 American Chemical Society.

However, at the slightly acidic pH$_e$, PEG molecules are removed from the surface of the NPs because of their acid-cleavable DMMA linker, promoting the intracellular delivery of the siRNA. Reprinted with permission from Ref. 106. Copyright © 2012 American Chemical Society.

**Figure 8** Scheme of siRNA-loaded PEGylated NPs that shows reduced non-specific interactions with blood proteins at physiological pH. However, at the slightly acidic pH$_e$, PEG molecules are removed from the surface of the NPs because of their acid-cleavable DMMA linker, promoting the intracellular delivery of the siRNA. Reprinted with permission from Ref. 106. Copyright © 2012 American Chemical Society.

4.2.2. pH-Induced activation of ligands

This approach uses pH sensitive structures to protect the active targeting moieties of the nanocarriers during blood circulation until they reach the acid tumoral microenvironment that activates the ligands to promote the internalization of the nanocarriers (Supporting Information Table S6).

Quan et al.103 described the synthesis of DOX-loaded PEGylated micelles, based on an α-β cyclodextrin dimer and a modified N-isopropylacrylamide-co-N-acryloyloxysuccinimide (P(NIPAam-co-NAS), that included a RGD peptide (Arg-Gly-Asp) as the targeting ligand to enhance the cellular uptake of the nanocarrier. In the micelles the RGD peptide was protected by PEG chains at physiological pH during blood circulation, but the ligand was exposed at pH below 6.8 due to the PEG removal after the hydrolysis of the benzoic-imine bonds that were used for PEGylation, enhancing the cellular uptake of micelles by endocytosis at pH$_e$ in HeLa cells. Moreover, the detachment of PEG molecules from the micelles changed their critical solution temperature from 38 °C at pH 7.4−35.5 °C at pH$_e$, which generated a temperature-induced release of DOX since micelles were stable at physiological conditions but their structure was disassembled at pH below 6.8. The authors observed a significant decrease (74%) in cell viability of HeLa cells when incubated with the DOX-loaded micelles at pH 6.8 and temperatures above 37 °C.

Using a completely different approach, Zhang et al.104 prepared silica NPs loaded with DOX and functionalized with β-
cyclo-dextrin (β-CD) via disulfide bond and then with two peptide sequences, Arg-Gly-Asp (RGD) and Pro-Leu-Gly-Val-Arg (PLGVR) via host-guest complexation. To protect the targeting moiety (RGD), poly (aspartic acid) (PASP) was included via click chemistry to PLGVR. During blood circulation, the silica NPs were shielded from non-specific cellular uptake, but at pH e, they were internalized by SCC-7 and HT-29 cancer cells. At this pH e, the PLGVR is hydrolyzed by the action of matrix metalloproteinases (MMPs), which leads to the exposure of the RGD moiety (53.6% of PASP was detached from NPs after 4 h with MMP-2) and uptake of the NPs. Once internalized, the DOX loaded in the pores of the silica NPs can be released by the cleavage of the disulfide bond with the action of GSH that removes the β-CD that close the pores (70% of DOX was released with 10 mmol/L GSH in 1 h, while no release was produced in the absence of GSH). Moreover, the authors demonstrated that these NPs have a potent cytotoxic effect on SCC-7 and HT-29 cells, since only the 40%–50% of cells remain viable after their treatment with the DOX-loaded silica NPs at a dose of DOX of 2.5 μg/mL.

Recently, Pan et al. synthesized by the nanoprecipitation method smart NPs composed of a ω-ω-tocopherol polyethylene glycol succinate-poly (histidine)-folate (TPGS-Phis-folate) tri-block copolymer plus a methoxypoly (ethylene glycol)-poly (ω,ω-lactic acid) (mPEG-PLA) diblock copolymer. PEG was included on the surface of the NPs to increase the blood circulation lifetime of the NPs, while the poly (histidine) block was added for the pH-dependent release of the cytotoxic drug and the pH-dependent activation of folate, the active targeting moiety that is hidden under the PEG layer at the physiological pH. When poly (histidine) is protonated at the pH e in tumors, the swelling of the NPs under the PEG layer will be detached when exposed to the slightly acidic pH of the intracellular organelles, and therefore the release of the cytotoxic drug, doxetaxel, into the cytoplasm of the cells. These pH-sensitive doxetaxel-loaded NPs showed a pH-dependent cytotoxicity profile, with a 1.66- and 3.83-fold decrease in the cell viability at pH of 6.8 and 5.8, respectively, which pointed to a partial release of doxetaxel in the tumor microenvironment and the total release in the intracellular space.

4.2.3. pH-Induced PEG detachment

Another strategy to induce the uptake of the nanocarriers using the acidic pH of the tumor environment is to link the PEG chains by pH-sensitive structures (Supporting Information Table S7). The PEG will protect the nanocarriers in circulation, but this stabilization layer will be detached when exposed to the slightly acidic pH of the tumors to avoid the hindering of the internalization of the carriers by the cancer cells due to PEGylation.

In addition to its role in modifying the surface charge of the nanocarriers from negative to positive, Dmma is also used to remove the stealth PEG layer of nanocarriers once in the extracellular tumor microenvironment and thus, increase their cellular uptake.

Yang et al. coated thiolated polyethyleneimine/siRNA NPs with the pH-sensitive PPC-Dmma, which is composed of the PEGylated poly (2-(2-aminoethoxy)ethoxy)phosphazene (mPEG-PAEP) diblock copolymer, cysteamine and Dmma. This formulation was used for the delivery of Polo like kinase 1 (Plk1) siRNA into MDA-MB-231 cells and MDA-MB-231 xenografts. At physiological pH, the NPs showed a reduction in the nonspecific interactions with blood proteins because of the PEG chains, facilitating their blood circulation, while at the tumor pH e, the PEG molecules detached and the siRNA-loaded NPs displayed a positive charge at their surface, promoting the intracellular uptake of siRNA and increasing the efficiency of gene silencing in MDA-MB-231 cells and mice with MDA-MB-231 xenografts, where the formulation reduced tumor growth, decreasing proliferation and increasing cell death (Fig. 8).

Using a similar approach, Fan et al. described positively charged microRNA (miR-34a)-loaded NPs based on β-cyclo-dextrin and polyethyleneimine (PEI). As Yang and co-workers, they coated these NPs with a negatively charged PEG derivative modified with Dmma (PPC-Dmma) that include pH-sensitive characteristics. The Dmma-modified PEGylated layer of the NPs protects them from the non-specific adsorption of proteins at physiological pH during blood circulation (24 h) and can be removed at pH e, enhancing their cellular uptake, by the cleavage of the amide bonds in the PPC-Dmma block copolymer, which generates a charge reversal from negative to positive. The authors showed the enhanced cellular uptake of the NPs at pH 6.8 in CD44-expressing B16F10 melanoma cells compared to the values obtained at pH 7.4, increasing the intracellular release of miR-34a and, therefore, reducing the CD44 expression. In vivo, using mice bearing B16F10 xenografts, the complexes accumulated in the tumors and exhibited a 1.6-fold tumor growth inhibition compared to free miR-34a.

4.3. pH-Sensitive size reduction for tumor penetration of nanocarriers

Another problem to deliver cytotoxic drugs to cancerous cells is their ability to overcome the poor vasculature and dense extracellular matrix in tumors to reach the inside of the tumoral mass. Nanocarriers can be engineered to change their size as a function of the acidic pH of the tumor microenvironment. At physiological pH, particle size is larger in order to possess optimal pharmacokinetic and pharmacodynamic properties, but, at pH e, the particles decrease in size below 30 nm to circumvent the biological barriers and penetrate in the tumoral mass.

Li et al. synthesized a platinum prodrug-conjugated poly (ethylene glycol)-b-poly (2-azepane ethyl methacrylate)-modified polyamido-amine (PEG-b-PAEMA-PAMAM/Pt) dendrimers with an enhanced tumor penetration capacity in the pH e range because of the pH-sensitive PAEMA block. This structure is self-assembled at pH 7.4 with a diameter of 80 nm, but is rapidly dissociated into its building blocks (10 nm of size) at pH 6.7, which led to a deep tumor penetration (85 μm) and up to 2.9-fold enhanced cell internalization of Cy5-labeled PEG-b-PAEMA-PAMAM dendrimers in pancreatic BxPC-3 multicellular spheroids at this pH e, compared to the free Cy5 or Cy5-labeled pH-insensitive dendrimers that were only located at the surface of the spheroids. Moreover, the PEG-b-PAEMA-PAMAM/Pt dendrimers exhibited a 2-fold increase in cell apoptosis (45%) at pH 6.7 in the spheroids, compared to the values obtained for Pt-conjugated pH-insensitive dendrimers or the PEG-b-PAEMA-PAMAM/Pt dendrimers at physiological pH. In vivo, these dendrimers showed a long circulation time in blood of more than 7 h in mice and a strongly inhibited tumor growth (up to 82% at a dose of 2 mg/kg) in mice bearing a pancreatic BxPC-3 xenograft compared to free cisplatin (24% at a dose of 2 mg/kg).
In another report this research group reported platinum prodrug-loaded clustered nanoparticles based on poly (amidoamine)-(2-propionic-3-methylmaleic anhydride)-polycaprolactone (PAMAM-CDM-PCL), PCL homopolymer and poly (ethylene glycol)-b-poly (ε-caprolactone) (PEG-b-PCL) copolymer. This system showed 100 nm of size and high stability at physiological pH during blood circulation (half-life higher than 10 h) due to the PEG-b-PCL layer but, at the pHH and because of PCL, was disassembled in 5 nm platinum prodrug-functionalized PAMAM dendrimers with a 10-fold enhanced penetration in BxPC-3 pancreatic cancer cells spheroids compared to non-pH sensitive clustered nanoparticles. Once internalized, the dendrimers were reduced, releasing the cytotoxic cisplatin. The pH-sensitive clustered nanoparticles exhibited significant tumor inhibitions of 88% or 95% in mice bearing BxPC-3 tumors or cisplatin-resistant A549R lung tumors compared to free cisplatin (38% or 10%) or non-sensitive clustered nanoparticles (57% or 60%)109.

5. Conclusions and future perspectives

Many works have been published in the last decade regarding the use of nanocarriers as an effective approach to specifically deliver anticancer drugs to tumors11. The success of this approach for targeted and/or safe delivery of chemotherapeutic drugs is stressed by the fact that some liposomal or PEGylated formulations are already being used in hospitals worldwide, but in addition, many clinical trials are being carried using encapsulated cytotoxic drugs12. Targeted delivery can only be achieved when the nanocarriers are able to distinguish between normal and tumoral tissues, and the differences in intra- and extracellular pH is a common characteristic of solid tumors of which researchers can take advantage to design delivery systems. Thus, almost a thousand articles come up when searching for nanocarriers and pH only in the title in PubMed, which is a testimony to the relevance of this approach as a therapeutic option.

In this monograph we have included some examples that illustrate the vast application of the drug delivery systems to the pH-based paradigm in cancer, focusing on a) the generation of acid stress inside the cancerous cells by proton-caged carriers, b) the inhibition of the proton extruder systems to promote acid-induced apoptosis in cancerous cells as well as to increase the acidic pHH and avoid the MDR by different nano-scale platforms, normally used as adjuvant therapy to cytotoxic drugs, and c) the utilization of the anomalous slightly acidic extracellular milieu in cancer to generate a controlled intracellular drug delivery.

Despite the vast amount of work done on proton pumps and their role in the pH changes observed in the tumoral extracellular environment and in cancer progression, there are no inhibitors approved for their use in cancer treatment. Moreover, among the transporters mentioned in this review, only carbonic anhydrase inhibitors are being tested in clinical trials as potential anticancer drugs. As we have mentioned before, vacuolar ATPases and Na\(^+\)/H\(^+\) exchangers are overexpressed in several types of cancer (Tables 2 and 3) and are likely responsible, at least in part of the extracellular acidification observed in cancer. This stresses the need of further research on these families in order to find and test new inhibitors capable of blocking cancer growth and dissemination.

Most of the approaches to use the extracellular acidic pH of tumors for a targeted delivery of cytotoxic drugs have shown a higher efficiency of the drug-loaded pH sensitive carriers than the administration of the free drugs, validating the use of extracellular pH changes to target tumors and avoid toxicity. But in spite of the success in treating cells in culture or mouse cancer models, these pH-based strategies for drug delivery have only reached preclinical stages, and to the best of our knowledge, to date no clinical trials involving pH sensitive drug delivery systems have been performed. This important step is a common barrier where most new drugs or therapeutic strategies end their development. Thus, unexpected toxicity not observed in mice, ineffectiveness in human beings or inability to scale up the synthesis of the compounds are some of the most frequent insurmountable barriers that researchers find that block the advance to clinical trials. This is a young area of interest in cancer therapeutics and future work is needed to optimize this therapeutic option and make it useful for cancer treatment.

The anomalous metabolism of cancer cells opens up a large number of new opportunities and strategies to fight against cancer as a unique illness. Although some of these approaches were not included in this monograph because they are less explored in association with drug delivery systems, we would like to, at least, mention them as future perspectives in this promising field. The induction of lysosomal membrane permeabilization (LMP), which has usually been achieved by the utilization of lysomotropic detergents, is one of the strategies to produce intracellular acidification and induce apoptosis, but it entails numerous side effects due to its lack of specificity. Although superparamagnetic iron oxide NPs (SPIONs) have been used for the generation of hyperthermia and magnetic-induced controlled drug release, they have not been widely explored for LMP, being this approach of great interest. In fact, epidermal growth factor (EGF)- or lysosomal protein marker LAMP1-conjugated SPIONs can be targeted to lysosomes and exposed to low frequency alternating magnetic fields (AMF) to generate rotation of the NPs inside the organelles that destabilize their membranes producing important mechanical damage111–114. A recent approach to revert the abnormal metabolic behavior in cancer cells is the inhibition of the shift of the oxidative phosphorylation to the aerobic glycolysis by the delivery to the mitochondria of dichloroacetate (DCA), an inhibitor of the pyruvate dehydrogenase kinase (PDK). The numerous problems regarding to the bioavailability, stability and intracellular uptake to the mitochondria of this compound can be resolved by the vehiculization of DCA by backbone carriers conjugated to DCA, pro-haloacetate NPs or nanomicelles generated from polymer−DCA conjugates that successfully target the mitochondria of cancer cells and interact with the PDK protein, increasing the oxidative phosphorylation process and inducing apoptosis of the malignant cells115–118. Although, the acidic tumoral pHH has been typically used to generate a pH-induced focalized and controlled drug release by pH-sensitive carriers, some research is currently underway to reverse this anomalous pH by using aqueous-stable calcium carbonate NPs with buffering capacity in order to minimize the MDR119,120. Despite the present lack of drugs or nanocarriers using extracellular acidification as a therapeutic approach in the clinical practice, this pH reduction in the tumor microenvironment is a common characteristic of solid tumors, and, thus,
The reverse intra/extracellular pH in tumors and targeted nanocarriers

ofers a unique weakness that can’t be overshadowed in the global race to find a cure for cancer.

Author contributions

Dr. Pérez-Herrero and Dr. Fernández-Medarde wrote and revised the manuscript. All authors have read and approved the final text and consent to its publication.

Conflicts of interest

These authors have no conflicts of interest to declare in this work.

Appendix A. Supporting Information

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2021.01.012.

References

1. Anandakrishnan R, Varghese RT, Kinney NA, Garner HR. Estimating the number of genetic mutations (hits) required for carcinogenesis based on the distribution of somatic mutations. PLoS Comput Biol 2019;15:e1006881.
2. Irazoju J, Martincorena I, Koonin EV. Cancer-mutation network and the number and specificity of driver mutations. Proc Natl Acad Sci U S A 2018;115:E6010.
3. Harguindeguy S, Reshkin SJ. “The new pH-centric anticancer paradigm in Oncology and Medicine”; SCB, 2017. Semin Cancer Biol 2017;43:1–4.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
5. Bellou S, Pentheroudakis G, Murphy C, Fotsis T. Anti-angiogenesis in cancer therapy: heroes and hydra. Cancer Lett 2013;338:219–28.
6. Huang M, Deng J, Gao L, Zhou J. Innovative strategies to advance CAR T cell therapy for solid tumors. Am J Cancer Res 2020;10:1970–92.
7. Dumas JF, Brisson L, Chevalier S, Mahéo K, Fromont G, Moussaïda D, et al. Metabolic reprogramming in cancer cells, consequences on pH and tumour progression: integrated therapeutic perspectives with dietary lipids as adjuvant to anticancer treatment. Semin Cancer Biol 2017;43:90–110.
8. Harguindeguy S, Stanciu D, Devesa J, Alfarouk K, Polo Stransky L, Cotter K, Forgac M. The function of V-ATPases in physiology and disease. Biochim Biophys Acta Biomembr 2011;1812:646.
9. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe N, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003;29:541–9.
10. Stranksy L, Cotter K, Forgac M. The function of V-ATPases in cancer therapy—progress and limitations. Semin Cancer Biol 2017;43:66–73.
11. Alai MS, Lin WJ. A novel nanoparticulate system for sustained delivery of acid-labile lansoprazole. Colloids Surf B Biointerfaces 2013;111:453–9.
12. Alai M, Lin WJ. Novel lansoprazole-loaded nanoparticles for the delivery of gastric acid secretion-related ulcers: in vitro and in vivo pharmacokinetic pharmacodynamic evaluation. AAPS J 2014;16:361–72.
13. Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 2015;93:52–79.
14. Scaife P, Stewart S, Rauch C. Focal photodynamic intracellular acidification as a cancer therapeutic. Semin Cancer Biol 2017;43:147–56.
15. Du JZ, Li HJ, Wang J. Tumor-acidity-cleavable maleic acid amide (TACMAA): a powerful tool for designing smart nanoparticles to overcome delivery barriers in cancer nanomedicine. Acc Chem Res 2018;51:2848–56.
16. Taylor S, Spagnini EP, Assaraf YG, Azzarito T, Rauch C, Fais S. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updates 2015;23:69–78.
17. Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A. Therapeutic implications of tumor interstitial acidification. Semin Cancer Biol 2017;43:119–33.
18. Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapi-
36. Yu M, Lee C, Wang M, Tannock IF. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. *Cancer Sci* 2015;106:1438–47.

37. Bhattacharya S, Khanam J, Sarkar P, Pal TK. A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics. *RSC Adv* 2019;9:240–54.

38. Loo SY, Chang MK, Chua CS, Kumar AP, Pervaiz S, Clement MV. NHE-1: a promising target for novel anti-cancer therapeutic.*Curr Pharm Des* 2012;18:1372–82.

39. Amiss SR, Fliegel L. NaHCO3/NaOH exchanger-mediated hydrogen ion extrusion as a carcinogenic signal in triple-negative breast cancer etiopathogenesis and prospects for its inhibition in therapies. *Semin Cancer Biol* 2017;43:35–41.

40. Chen Q, Liu Y, Zhu XJ, Feng F, Yang H, Xu W. Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo. *BMC Cancer* 2019;19:211.

41. Tate JG, Bamford S, Jubb HC, Sonoda Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. *Nucleic Acids Res* 2019;47(D1):D941–7.

42. Zheng T, Jäättelä M, Liu B. pH gradient reversal fuels cancer progression.*Int J Biochem Cell Biol* 2020;125:105796.

43. Perez-Escuredo J, Van Hee VF, Sboarina M, Falces J, Payaen VL, Mina E, et al. Monocarboxylate transporters in the brain and in cancer.*Biochim Biophys Acta* 2016;1860:10–16.

44. Calori IR, Piva HL, Tedesco AC. Targeted cancer therapy using alpha-cyano-4-hydroxycinnamic acid as a novel vector molecule: a proof-of-concept study. *J Drug Deliv Sci Technol* 2020;57:101633.

45. Guan X, Morris ME. In vitro and in vivo efficacy of AZD3965 an alpha-cyano-4-hydroxycinnamic acid in the murine 4T1 breast tumor model. *AAPS J* 2020;22:84.

46. Payen VL, Mina E, Van Hee VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. *Mol Metab* 2020;9:48–66.

47. Clinical trials. Available from: https://www.clinicaltrials.gov. [Accessed 3 October 2020].

48. Huang T, Feng Q, Wang Z, Li W, Sun Z, Wilhelm J, et al. Tumor-targeted inhibition of monocarboxylate transporter 1 improves T-cell immunotherapy of solid tumors. *Adv Healthc Mater* 2020;10:200549.

49. Mboge MY, Mahon BP, McKenna R, Frost SC. Carboxylic anhydrides: role in pH control and cancer. *Metabolites* 2018;8:19.

50. GEO profile dataset. Available from: https://www.ncbi.nlm.nih.gov/geo. [Accessed 10 October 2020].

51. Oosterwijk E. Carboxylic anhydride expression in kidney and renal cancer: implications for diagnosis and treatment. In: Frost SC, McKenna R, editors. *Carboxylic anhydride: mechanism, regulation, links to disease, and industrial applications*. Dordrecht: Springer Netherlands; 2014.

52. Tatiparti K, Rauf MA, Sau S, Iyer AK. A Biomimetic drug delivery system targeting tumor hypoxia in triple-negative breast cancers. *Adv Funct Mater* 2020;25:1163–21.

53. Ellis-Davies GCR. Caged compounds: photorelease technology for control of cellular chemistry and physiology. *Nat Methods* 2007;4:619.

54. Agasti SS, Chompooasor A, You CC, Ghosh P, Kim CK, Rotello VM. Photoregulated release of caged anticancer drugs from gold nanoparticles. *J Am Chem Soc* 2009;131:5728–9.

55. Barth A, Corrie JE. Characterization of a new caged proton capable of inducing large pH jumps. *Biochim J* 2002;83:2864–71.

56. Carbone M, Zlateva T, Quaroni L. Monitoring and manipulation of the pH of single cells using infrared spectromicroscopy and a molecular switch. *Biochim Biophys Acta Gen Subj* 2013;1830:2899–903.

57. Carbone M, Sabbatella G, Antonaroli S, Remita H, Orlando V, Biagioni S, et al. Exogenous control over intracellular acidification: enhancement via proton caged compounds coupled to gold nanoparticles. *Biochim Biophys Acta Gen Subj* 2015;1850:2304–7.

58. Sulpiano EA, Antonaroli S, Diociati M, Nucara A, Carbone M. Synthesis of proton caged disulphide compounds for gold nanoparticle functionalization. *New J Chem* 2015;39:2406–16.

59. Zhou L, Hu H, Zhang YX, Meng QY, Yu B, Shen YQ, et al. A near-infrared triggered intracellular pH regulatory PAMAM/O-nitrobenzaldehyde coated UCNPs for cancer therapy. *Integrated Ferroelectrics* 2019;199:85–94.

60. Lee KS, Na K, Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. *J Control Release* 2003;91:103–13.

61. Yin H, Lee ES, Kim D, Lee KH, Oh KT, Bae YH. Physicochemical characteristics of pH-sensitive poly(ε-histidine)-b-poly(ethylene glycol)/poly(ε-lactide)-b-poly(ethylene glycol) mixed micelles. *J Control Release* 2008;126:130–8.
The reverse intra/extracellular pH in tumors and targeted nanocarriers

75. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. *J Control Release* 2005;103:405–18.

76. Lee ES, Oh KT, Kim D, Youn YS, Bae YH. Tumor pH-responsive flower-like micelles of poly(lactic acid)-b-poly(ethylene glycol)-b-poly(L-histidine). *J Control Release* 2007;123:19–26.

77. Yin H, Kang HC, Huh KM, Bae YH. Biocompatible, pH-sensitive AB2 miktoarm polymer-based polymersomes: preparation, characterization, and acidic pH-activated nanostructural transformation. *J Mater Chem* 2012;22:19168–78.

78. Johnson RP, Uthaman S, John JV, Lee HR, Lee SJ, Park H, et al. Poly(PEGA)-b-poly(L-lysine)-b-poly(L-histidine) hybrid vesicles for tumoral pH-triggered intracellular delivery of doxorubicin hydrochloride. *ACS Appl Mater Interfaces* 2015;7:21770–9.

79. Hwang J-H, Choi CW, Kim H-W, Kim DH, Kwak TW, Lee HM, et al. A self-targeting cationic micelle of poly(L-lysine)-block-polyepsilon-caprolactone for targeted tumor drug delivery. *Int J Nanomed* 2013;8:3197–207.

80. Lee ES, Kim JH, Sim T, Youn YS, Lee BJ, Oh YT, et al. A feasibility study of a pH sensitive nanomedicine using doxorubicin loaded poly(aspartic acid-graft-imidazole)-block-poly(ethylene glycol) micelles. *J Mater Chem* 2014;2:1112–9.

81. Kim JH, Oh YT, Lee KS, Yun JM, Park BT, Oh KT. Development of a pH-sensitive polymer using poly(aspartic acid-graft-imidazole)-block-poly(ethylene glycol) for acidic pH targeting systems. *Macromol Res* 2011;19:453–60.

82. Ko J, Park K, Kim Y-S, Kim MS, Han JK, Kim K, et al. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-polylamino ester) block copolymer micelles for cancer therapy. *J Control Release* 2007;123:109–15.

83. Mio KH, Kim I-H, Bae SM, Shin H, Kim MS, Park S, et al. Tumoral acidic pH-responsive MPEG-poly(β-amino ester) polymeric micelles for cancer targeting therapy. *J Control Release* 2010;144:259–66.

84. Lee JO, Oh KT, Kim D, Lee ES. pH-sensitive short worm-like micelles targeting tumors based on the extracellular pH. *J Mater Chem* B 2014;2:6363–70.

85. Wang J, Xu W, Guo H, Ding J, Chen J, Guan J, et al. Selective intracellular drug delivery from pH-responsive polyelectrolyte complex micelle for enhanced malignancy suppression in vivo. *Colloids Surf B Biointerfaces* 2015;135:283–90.

86. Bilalis P, Tziveleka LA, Varlas S, Iatrou H. pH-Sensitive nanogates and controllable drug delivery system constituting mesoporous silica nanoparticles. *Polym Chem* 2016;7:1475–85.

87. Chen T, Wu W, Xiao H, Chen Y, Chen M, Li J. Intelligent drug delivery system based on mesoporous silica nanoparticles coated with an ultra-pH-sensitive gatekeeper and poly(ethylene glycol). *ACS Macro Lett* 2016;5:55–8.

88. Chen C, Yao W, Sun W, Guo T, Lv H, Wan X, et al. A self-targeting and controllable drug delivery system constituting mesoporous silica nanoparticles fabricated with a multi-stimuli responsive chitosan-based thin film layer. *Int J Biol Macromol* 2019;122:1090–9.

89. Uthaman S, Huh KM, Park I-K. Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications. *Biomater Res* 2018;22:22.

90. Liao J, Zheng H, Fei Z, Lu B, Zheng H, Li D, et al. Tumor-targeting and pH-responsive nanoparticles from hyaluronic acid for the enhanced delivery of doxorubicin. *Int J Biol Macromol* 2018;113:737–47.

91. Zhang M, Liu J, Kuang Y, Ki Q, Zheng DW, Song Q, et al. Ingenious pH-sensitive dextran/mesoporous silica nanoparticles based drug delivery systems for controlled intracellular drug release. *Int J Biol Macromol* 2017;98:691–700.

92. Du J, Lane LA, Nie S. Stimuli-responsive nanoparticles for targeting the tumor microenvironment. *J Control Release* 2015;219:205–14.

93. Wu W, Luo L, Wang Y, Wu Q, Dai HB, Li JS, et al. Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications. *Theranostics* 2018;8:3038–58.

94. Liu Y, Qiao L, Zhang S, Wang G, Chen B, Zhou P, et al. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. *Acta Biomater* 2018;66:310–24.

95. Wu W, Wang J, Lin Z, Li X, Li J. Tumor-acidity activated surface charge-conversion of polymeric nanocarriers for enhanced cell adhesion and targeted drug release. *Macromol Rapid Commun* 2014;35:1679–84.

96. Feng T, Ai X, An G, Yang P, Zhao Y. Charge-convertible carbon dots for imaging-guided drug delivery with enhanced in vivo cancer therapeutic efficiency. *ACS Nano* 2016;10:4410–20.

97. Hu J, Miura S, Na K, Bae YH. pH-responsive and charge shielded cationic micelle of poly(ethylene glycol)-block-short branched PEI for acidic cancer treatment. *J Control Release* 2013;172:69–76.

98. Ye G, Jiang Y, Yang X, Hu H, Wang B, Sun L, et al. Smart nanoparticles undergo phase transition for enhanced cellular uptake and subsequent intracellular drug release in a tumor microenvironment. *ACS Appl Mater Interfaces* 2018;10:278–89.

99. Du JZ, Sun TM, Song WJ, Wu J, Wang J. A Tumor-acidity-activated charge-conversional nanogel as an intelligent vehicle for promoted tumoral-cell uptake and drug delivery. *Angew Chem Int Ed* 2010;49:3621–6.

100. Yoon SR, Yang HM, Park CW, Lim S, Chung BH, Kim J-D. Charge-conversional poly(amino acid) derivatives as a drug delivery carrier in response to the tumor environment. *J Biomed Mater Res* 2012;100A:2027–33.

101. Huang H, Li Y, Sa Z, Sun Y, Wang Y, Wang J. A Smart drug delivery system from charge-conversion polymer-drug conjugate for enhancing tumor therapy and tunable drug delivery. *Macromol Biosci* 2014;14:485–90.

102. Qu J, Peng S, Wang R, Yang ST, Zhou QH, Lin J. Stepwise pH-sensitive and biodegradable polypeptide hybrid micelles for enhanced cellular internalization and efficient nuclear drug delivery. *Colloids Surf B Biointerfaces* 2019;181:315–24.

103. Quan CY, Chen JX, Wang HY, Li C, Chang C, Zhang XZ, et al. Core–shell nanized assemblies mediated by the α–β cyclodextrin dimer with a tumor-triggered targeting property. *ACS Nano* 2010;4:1211–9.

104. Zhang J, Yuan ZF, Wang Y, Chen WH, Luo GF, Cheng SX, et al. Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery. *J Am Chem Soc* 2013;135:5068–73.

105. Pan J, Lei S, Chang L, Wan D. Smart pH-responsive nanoparticles in a model tumor microenvironment for enhanced cellular uptake. *J Mater Sci* 2019;54:1692–702.

106. Yang XZ, Du JZ, Dou S, Mao CQ, Long HY, Wang J. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. *ACS Nano* 2012;6:771–81.

107. Fan M, Zeng Y, Ruan H, Zhang Z, Gong T, Sun X. Ternary nanoparticles with a sheddable shell efficiently deliver microRNA-34a against CD44-positive melanoma. *Mol Pharm* 2017;14:3152–63.

108. Li HJ, Du JZ, Liu J, Du XJ, Shen S, Zhu YH, et al. Smart superstructures with ultrahigh pH-sensitivity for targeting acidic tumor microenvironment: instantaneous size switching and improved tumor penetration. *ACS Nano* 2016;10:6753–61.

109. Li HJ, Du JZ, Du XJ, Xu CF, Sun CY, Wang HX, et al. Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. *Proc Natl Acad Sci U S A* 2016;113:4164.

110. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. *Bioeng Transl Med* 2019;4:e10143.
111. Domenech M, Marrero-Berrios I, Torres-Lugo M, Rinaldi C. Lyso-
somal membrane permeabilization by targeted magnetic nano-
particles in alternating magnetic fields. ACS Nano 2013;7:5091–101.
112. Zhang E, Kircher MF, Koch M, Eliasson L, Goldberg SN, Renström E. Dynamic magnetic fields remote-control apoptosis via
nanoparticle rotation. ACS Nano 2014;8:3192–201.
113. Cheng Y, Muroski ME, Petit DCMC, Mansell R, Vemulkar T,
Morshed RA, et al. Rotating magnetic field induced oscillation of
magnetic particles for in vivo mechanical destruction of malignant
glioma. J Control Release 2016;223:75–84.
114. Shen Y, Wu C, Uyeda TQP, Plaza GR, Liu B, Han Y, et al. Elongated
nanoparticle aggregates in cancer cells for mechanical destruction
with low frequency rotating magnetic field. Theranostics 2017;7:
1735–48.
115. Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S,
et al. Design, synthesis, and biological characterization of novel
mitochondria targeted dichloroacetate-loaded compounds with anti-
leukemic activity. J Med Chem 2016;59:147–56.
116. Misra SK, Ye M, Ostadhossein F, Pan D. Pro-haloacetate nano-
particles for efficient cancer therapy via pyruvate dehydrogenase
kinase modulation. Sci Rep 2016;6:28196.
117. Yang Q, Cai J, Sun S, Kang X, Guo J, Zhu Y, et al. Polymer
nanoparticle delivery of dichloroacetate and DACH-Pt to enhance
antitumor efficacy and lower systemic toxicity. Biomater Sci 2016;
4:661–9.
118. Bhat TA, Kumar S, Chaudhary AK, Yadav N, Chandra D. Restora-
tion of mitochondria function as a target for cancer therapy. Drug
Discov Today 2015;20:635–43.
119. Som A, Raliya R, Tian L, Akers W, Ippolit JE, Singamaneni S,
et al. Monodispersed calcium carbonate nanoparticles modulate
local pH and inhibit tumor growth in vivo. Nanoscale 2016;8:
12639–47.
120. Som A, Raliya R, Paranandi K, High RA, Reed N, Beeman SC, et al.
Calcium carbonate nanoparticles stimulate tumor metabolic reprog-
gramming and modulate tumor metastasis. Nanomedicine 2019;14:
169–82.